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Dentro de nós há uma coisa que não tem nome, essa coisa é o que somos 
Inside us there is a thing that does not have a name, this thing is what we are 
 - José Saramago 
 
 
  
ABSTRACT 
The mammalian body is a mosaic of different organisms - a holobiont, which contains all the 
biomolecules and their metabolites encoded in our eukaryotic genome and supplemented by an even 
larger pool of prokaryotic genes and products. This symbiotic coexistence is presumed to have 
evolved to necessitate the sharing of biological and biochemical needs important for growth, body 
physiology, survival and reproduction. In this thesis, the communication between the microbiome and 
its host has been studied using state-of-the-art high-throughput methodologies, modelled on two 
known ligand-activated transcription factors, AhR and PPARγ. We show that commensal bacteria and 
their metabolites, short chain fatty acids (SCFA) can induce the expression of ANGPTL4 and 
CYP1A1 in gut epithelial cells. These genes are regulated by PPARγ and AhR respectively. 
ANGPTL4 is known to regulate metabolic processes connected to energy storage and utilisation, 
whilst CYP1A1 is involved metabolism of toxins and pollutants. These results illustrate how innate 
and metabolic properties of intestinal cells can be modulated by gut microbial products. This model is 
further evaluated using the pathogen Salmonella enterica serovar Typhimurium. Infection studies in 
mice show that Salmonella inactivates PPARγ and  elicits acute colitis and activation of the protein 
lipocalin 2 (LCN2). LCN2 stabilises the metalloproteinase protein MMP9 which, in turn, further fuels 
tissue damage and colitis. Interestingly, the use of LCN2 KO mice drastically alleviates colitis. This 
highlights PPARγ/LCN2/MMP9 as a set of metabolic and immune regulators of the host that 
Salmonella needs to “hijack” in order to pave its way for intestinal colonisation. As PPARγ is a 
regulator of energy balance and LCN2 is an important metabolic regulatory protein, these studies 
establish a functional link between pathophysiology, metabolism, immune responses and gut 
microbes. In the final study, the bidirectional communication between the AhR signalling pathway and 
gut microbiome is explored. While the bacterial metabolite SCFA can regulate AhR function and 
expression of its target genes in intestine and liver, the composition of the gut microbiota is altered in 
AhR KO mice.  Furthermore, metabolomic studies of AhR KO mice show that these mice, when under 
metabolic stress are compromised in their ability to produce ketone bodies. The evidence of metabolic 
stress is further supported by the observation that young AhR KO mice show growth retardation at a 
developmental stage that is prone to dynamic fluctuations in microbiota composition.  These findings 
illustrate the link between immunity and metabolic functions through the sharing of biological and 
biochemical modulators within the holobiont. The re-discovery of the gut microbiome and its apparent 
influence on body functions represent a paradigm shift. We are just beginning to appreciate the 
importance of the microbiome as a mediator of health and are starting to understand how microbes 
contribute to who we are and how we function as one organism.  
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1 INTRODUCTION 
The gastrointestinal tract is a complex ecosystem where prokaryotic bacteria meet eukaryotic cells and 
interaction between them are influenced by nutrition, toxins and drugs. A delicate balance is created 
between the host defence machinery preparing itself against pathogenic invasions whilst at the same 
time providing a niche for trillions of commensal bacteria that will support the host in a symbiotic 
manner. Many receptors and signalling pathways are engaged in this process. Many more remain to be 
discovered. Two known guardians of intestinal homeostasis are the peroxisome proliferator-activated 
receptor gamma (PPARγ) and the aryl hydrocarbon receptor (AhR). These two proteins control many 
of the physiological processes taking place in the gut, including those at the inflammation-metabolism 
interface. They also respond to bacterial signals allowing for bidirectional exchange of signals and 
nutrients between the host and its microbiome, which is necessary for the maintenance of health. 
1.1 The gastrointestinal tract 
The gastrointestinal (GI) tract is a multifunctional organ with a complex structure and diverse 
physiological roles. Rather than a single organ, it is an ecosystem composed of three main 
components: host cells, microbiota and environmental cues, including nutrients. The main function of 
the gastrointestinal tract is to provide energy as well as micro- and macronutrients to the rest of the 
body. In recent years, however, it became apparent that the GI tract is much more than just a digestive 
and absorptive organ. The GI tract provides the first line of defence against natural toxins and man-
made chemicals. It also contains trillions of bacteria and maintains a balance between tolerogenic and 
inflammatory signals. This balance is necessary for  peaceful coexistence and exchange of signals 
between the host and the microbiome, which in turn ensures proper regulation of many physiological 
processes. The GI tract is also an endocrine organ, which produces signalling molecules 
communicating with the rest of the body, including the brain. All these functions are strongly related 
to the particular structure and morphology of the GI tract. 
1.1.1 Structure and morphology of the gastrointestinal tract 
In broad terms, the lower GI tract can be divided into the stomach, small intestine and colon (large 
intestine). Each of these compartments has a slightly different anatomy, role and physiology (Table 1).  
Table 1. Function, pH and dimensions of different parts of the human lower GI tract. 
 
 
Name Function pH Length (cm) Diameter (cm) 
Stomach 
HCl secretion, digestion of 
macromolecules 
2 variable variable 
Small 
intestine 
Main digestion. Absorbtion of 
monosaccharides, fatty acids, amino 
acids and water 
4-5 600 2,5 
Colon 
Absorbtion of water, vitamins and 
bile acids. 
7 150 7,5 
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The small intestine is further divided into duodenum, jejunum and ileum. The colon is divided into 
proximal and distal parts (ascending, transverse and descending colon in humans). From the 
anatomical point of view, the small and large intestine share a similar structure of a tube covered by 
many layers of distinct tissues. The main layers surrounding the intestinal lumen are mucosa, 
submucosa and smooth muscles. The mucosa is composed of a layer of smooth muscles, lamina 
propria, a single layer of epithelial cells separating the host from the environment and mucus - 
glycoprotein gel-like structure secreted to the lumen. The structure of the mucosal layer of the small 
intestine and colon vary significantly. The epithelial cells of the small intestine form villi and crypts. 
In the colon, the villi are absent. The mucus layer structure is also distinct in the small intestine and 
the colon (Figure 1) (1).  
 
 
 
Figure 1. Structure of the small intestinal and colonic mucosa. 
 
The epithelial cells are connected with each other by tight junctions to prevent leakage of large 
molecules in-between the cells into the lamina propria. Epithelial cells are not uniform and several 
types can be distinguished based on morphology and function: stem cells, enterocytes, 
enteroendocrine, goblet and Paneth cells. The stem cells are located at the bottom of the crypts and 
give rise to all the other cell types building the epithelial layer. The enterocytes are the most abundant 
cell type and function as absorptive cells, responsible for transport of nutrients from the lumen to 
lamina propria, from where they are further transported to the blood or lymph circulation. Goblet cells 
are specialised in producing mucins - the glycoproteins building the mucosal barrier. Enterocytes and 
goblet cells have a life span of 5 to 6 days. Enteroendocrine cells produce signalling molecules that 
regulate many digestive processes, e.g. release of enzymes from the pancreas. Paneth cells are present 
in the small intestine but not in the colon. They are situated at the bottom of the crypts, in proximity to 
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stem cells. Paneth cells are long lived cells, with a life span up to one month. Paneth cells produce 
antimicrobial peptides, which play an important role in protecting the host from invasion of 
pathogenic bacteria. In the colon, which lacks the Paneth cells, the antimicrobial peptides are secreted 
by enterocytes (2,3). Apart from epithelial cells, the first layer of contact between the host and the 
environment also consists of infiltrating immune cells, called intraepithelial lymphocytes (IEL). One 
other type of immune cells present in the lamina propria - dendritic cells are thought to produce 
protrusions between the epithelial cells to reach the lumen and sample the intestinal antigens. The 
sampling of antigens also occurs directly through a specific cell type called the M-cells. The presence 
of cells with immune function in the close proximity of bacterial and nutritional antigens assures 
proper tolerogenic responses within the gut. It also provides a very sensitive system for rapid detection 
of pathogenic bacteria invading the GI ecosystem.  
1.1.2 Gastrointestinal tract as a multifunctional organ 
The GI tract has been for many years regarded as a digestive organ. Recently, it has become apparent 
that the GI tract is much more than just an absorptive surface. Many metabolically active enzymes are 
expressed in the gut epithelium influencing the energy balance of the whole body. Harmful substances, 
like chemicals and toxins are also absorbed and/or metabolised in the epithelial cells of the gut. The GI 
tract is a place of bidirectional exchange of signals and nutrients between the host and the microbiota. 
One of the tasks of the GI tract is to maintain a balance between tolerance to nutritional and 
commensal antigens at the same time providing an effective defence system against pathogens. This 
balance is achieved thanks to a mucus layer and production of antimicrobial peptides by the epithelial 
cells as well as by the presence of competent immune cells in the lamina propria. Additionally, it has 
now became apparent that the GI tract communicates (via the vascular lymphatic system, vagus nerve, 
signalling peptides and others) with the rest of the body and influences many physiological processes. 
1.1.2.1 Digestive function of the GI tract 
The digestive function of the GI tract is its most well known and most studied function. Digestion of 
food starts with a breakdown of macromolecules like fat, carbohydrates and proteins into smaller 
molecules (fatty acids, simple sugars and peptides). This process begins already in the mouth and 
continues in the stomach and throughout the small intestine. Enzymes, like pepsin, are released from 
the pancreas and upon activation in the small intestine break down proteins. Bile acids are secreted 
from the gall bladder and facilitate the breakdown and absorption of fats. Most nutrients are absorbed 
to the circulation before reaching the colon. In the colon, water, vitamins and minerals are absorbed. It 
is also in the colon where the residing microbiota ferment proteins and complex carbohydrates, 
providing additional source of energy for the host in form of short chain fatty acids (SCFA).  
 
1.1.2.2 Xenobiotic metabolism 
The main function of the GI tract is to extract energy and minerals from ingested food. However, not 
everything that reaches the intestine has a nutritional value. Together with food and water we also 
ingest toxins, chemicals and environmental pollutants, collectively known as xenobiotics  (from Greek 
xeno meaning foreign). Xenobiotics (including medicines) introduced orally are a subject of so called 
first-pass metabolism in the gastrointestinal canal and liver before they reach the rest of the body. The 
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metabolism of xenobiotics is divided into two phases: I and II. In phase I xenobiotics are modified 
chemically (most commonly hydroxylated, deaminated, oxidated or dealkylated). These chemical 
modifications allow for the phase II reactions in which xenobiotics are conjugated with a water-
soluble molecules (UDP-glucuronic acid, acetyl-coA, glycin or sulphates to name a few) to be further 
exported out from the cells to the blood stream or back to the intestinal lumen. Many of the genes 
coding phase I and phase II enzymes, as well as specific transporters for conjugated xenobiotics are 
expressed in the epithelial cells of the GI tract. In general, the expression and activity of xenobiotic 
metabolising enzymes decreases with descending from duodenum towards the ileum (4,5). The most 
important group of phase I enzymes is the family of cytochrome P450 proteins (CYP450). There are 
57 members of CYP450 family in human and 102 in mice 
(http://drnelson.uthsc.edu/CytochromeP450.html). The CYP450 genes are divided into 18 families and 
43 subfamilies. The most important ones from the pharmacological point of view are enzymes 
belonging to CYP1, CYP2, CYP3 families (6). CYP1 genes are expressed in the epithelial cells of the 
GI tract of mice and humans and are responsible for metabolism of drugs and steroids, especially 
oestrogen (7,8). CYP1 proteins are divided into 3 subfamilies: CYP1A1, CYP1A2 and CYP1B1. 
Metabolism of xenobiotic in the epithelial cells of the GI tract can be protective or detrimental to the 
host, depending on the type of substance. Additionally, some xenobiotics are metabolised by bacteria 
resident in the GI tract (9,10).  
1.1.2.3  Mucosa: the intestinal gatekeeper 
The characteristic anatomy of the gastrointestinal tract with villi and crypts forms an enormous 
inhabitable surface of around 200m
2
 (11). This surface and the lumen of the gut are densely populated 
by bacteria, fungi and protozoa. Bacteria inhabiting the gut outnumber our own cells 10 times and 
contain 100 times more genes. We harbour around 1,5 kg of bacteria in our gut, more than 10
12
 
cells/cm
3
 of colonic content. On the other hand, our "insides" are separated from the lumen and 
inhabiting microbiota by a single layer of cells, about 10µm thick. To make their task of protecting the 
host from bacterial invasion even more difficult, the epithelial cells do not remain steady, but are in 
constant movement from the crypts to the top of the villi, during which time they differentiate. The 
epithelial lining is exchanged by new cells every week, proving great challenge of keeping the 
intestinal barrier intact. The bacterial community also fluctuates, responding to changes in diet, 
antibiotic intake or presence of opportunistic pathogens (12,13). Even though we are in constant alert 
to spot the potentially dangerous bacteria, we must remember that the majority of bacteria inhabiting 
our intestines are neutral or beneficial for our health, providing vitamins and nutrients (like SCFA). 
The intestinal defence system must therefore have a way to distinguish between the "good" and the 
"bad" bacteria, allowing for the growth of the first, and preventing invasion of the latter. During many 
years of evolution a system that provides means to maintain the correct balance between the host and 
the microbiome in the GI tract has developed. This system is composed of many elements: mucosal 
layer, antimicrobial peptides, pattern recognition receptors and gut associated immune tissues, to name 
a few. 
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1.1.2.3.1 The mucus layer 
The surface of the GI tract is covered by a layer of mucus, a gel-like structure protecting the thin 
epithelial lining from the invasion of bacteria. This layer is composed of cross-linked glycoproteins, 
called mucins where the oligosaccharide part forms up to 80% of the molecule (14). Mucins are 
produced and secreted by goblet cells. The mucus layer in the small intestine is not organised in any 
specific way but scattered randomly among the villi (1). In the colon, however, mucus is organised in 
two distinguishable layers - dense, bacteria free layer closest to the epithelial cells, and loose mucin 
layer, where the commensal bacteria reside (Figure 1) (15). The thickness of the mucosal layer in the 
colon reaches up to 150µm (16). It can, however, be diminished by antibiotic treatment, predisposing 
the host to bacterially-induced colitis (17). Thinner mucosal layer is also observed in patients with 
inflammatory bowel disease (IBD) (18). The mucosal layer is however not only an important barrier 
that keeps bacteria at distance from the epithelial lining. It also provides a habitat for mucin degrading 
bacteria. Glycans forming the mucosal layer represent an important energy source for commensal 
bacteria, which in turn produce SCFA, providing energy for colonocytes. In this way, part of the 
energy lost in the process of mucin production is re-gained by the host (1,19,20). Mucus has one more 
important function. It provides a matrix on which antimicrobial peptides secreted from epithelial cells 
are concentrated preventing translocation of bacteria to the proximity of epithelial cells (21). 
1.1.2.3.2 Antimicrobial peptides 
Antimicrobial peptides (AMPs) produced by the epithelial cells are natural antibiotics, with a task to 
kill or deactivate invading bacteria. In contrast to antibiotics used in clinics, to which bacteria fast 
develop resistance, very few bacterial species are resistant to AMP indicating how important AMPs 
are in basic defence against pathogens (3,22). One of the few pathogenic species that did develop 
resistance to many of the AMPs is Salmonella enterica (23). AMPs are evolutionally conserved and 
can be found in all organisms, from plants to mammals (24). AMPs are found on the skin, in the 
intestine, respiratory and reproductive tracts. Some of the AMPs are expressed constitutively, i.e. 
independently from microbial presence. For some AMPs, however, specific bacterial signals are 
required to induce their expression and secretion to the lumen. Many AMPs are secreted in response to 
bacterial signals sensed by pattern recognition receptors, present on epithelial cell and cells of the 
immune system.  
There are several groups of AMPs with different functions and structure, corresponding to the 
diversity of the bacterial communities. The most prevalent group of AMPs is formed by α-defensins, 
also known as cryptidins in mice. α-defensins are positively charged molecules that bind to bacterial 
cell membranes which are charged negatively. This causes membrane disruption, being effective 
against both Gram-positive and Gram-negative bacteria, some fungi, viruses and protozoa. α-defensins 
are mostly present in the small intestine where they are produced by Paneth cells (25). In the colon, 
which lacks Paneth cells, β-defensins are produced instead by the enterocytes. 
Another group of AMPs are C-type lectins, including regenerating islet-derived protein family (REG). 
The most important example of a protein belonging to this group is REG3γ in mice and REG3α in 
humans, both secreted from enterocytes and Paneth cells of the small intestine (26). In the colon, their 
expression is induced in enterocytes upon infection (27). REG proteins are most efficient in killing 
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Gram-positive bacteria, because they bind peptidoglycans, one of the components of bacterial cell wall 
of Gram-positive bacteria (28).  
Apart from disrupting the bacterial cell membrane, other AMPs fight the bacteria by different 
mechanism, for example by interfering with mineral supply. Lipocalin 2 (LCN2) is an example of 
such an AMP, which when secreted from enterocytes and immune cells sequesters iron-laden 
siderophores, making iron inaccessible for bacteria (29). This sequestration is believed to dampen 
growth and invasion of intestinal pathogens. 
AMPs can also exert their functions indirectly, by stimulating the immune responses of the host. 
Defensins have chemo-attractant properties and recruit leukocytes to the site of infection. Deregulation 
in AMPs production and activity can lead to breakage of self-tolerance and development of 
autoimmune disorders (30).  
1.1.2.3.3 Pattern recognition receptors 
Pattern recognition receptors (PRRs) are proteins expressed in epithelial and immune cells with a 
function of recognising microbial presence, by binding to microbe-associated molecular patterns 
(MAMPs). MAMPs are generally conserved structures of bacterial cells, like cell wall components 
(e.g. lipopolisaccharide and peptidoglycan), flagella or microbial DNA and RNA molecules. There are 
two main families of PRRs - Toll like receptors (TLRs) and nuclear oligomerisation domain-like 
receptors (NLRs).  Once MAMPs are detected a cascade of signalling events is activated inside the 
host cell leading to the production of defence molecules, like mucins, AMPs, immunoglobulins or 
cytokines, depending on the type of activated cell (31,32). One of the most important cytokines for the 
maintenance of immunological balance between inflammation and tolerance in the gut is interleukin-
22 (IL-22), which is produced by specific type of cells called innate lymphoid cells (ILC). 
1.1.2.3.4 Innate lymphoid cells 
Apart from defence system provided by the epithelial cells, the lamina propria of the intestine hosts a 
variety of immune cells. One of the cell types crucial for the maintenance of intestinal homeostasis are 
innate lymphoid cells (ILCs) (33). There are three families of ILCs, characterised by activity of 
specific transcription factors and production of cytokines. Group 3 ILCs expresses Retinoic acid-
related Orphan Receptor gamma t (RORγt) and aryl hydrocarbon receptor (AhR) transcription factors 
and produce IL-22 and IL-17A in response to bacteria (34). IL-22 stimulate production of mucins and 
AMPs in the IEC which express the IL-22 receptor (35).The cross-talk between ILCs and the intestinal 
flora is bidirectional. Bacterial signals influence the function of ILCs, and the activity of ILCs changes 
the composition of the microbiota in the gut (33). 
 
1.1.2.3.5 Other components of the immune system 
Epithelial cells and ILCs provide very important defence systems against invasion of potentially 
harmful bacteria. Many other cell types participate in protection of the host against pathogens. These 
include adaptive immune cells and innate immune cells, like dendritic cells (DC) or macrophages. One 
of the most important cell type within the adaptive immune system are B-cells, which produce 
immunoglobulins (Ig). In the gut, it is IgA, that plays the most important role in host's protection.  
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IgA is secreted to the lumen where it causes bacterial agglutination and trapping in the mucus (36,37) 
Another adaptive immune cell type that is important for the intestinal homeostasis are T-cells, 
especially T helper -17 (Th17 cells) and T regulatory cells (Tregs in the small intestine and Tr1 in the 
colon). T regulatory cells are crucial for the development of tolerance to commensal bacteria, nutrients 
and other molecules that can be found in the intestinal lumen. The development of tolerance is directed 
via production of interleukin 10 by these cells (38).  
1.2 The Microbiome 
Mucosal surfaces, like skin and respiratory, uro-genital, and gastrointestinal tracts, are constantly in 
touch with bacteria, viruses, fungi and protozoa. In fact, our bodies contain more prokaryotic than 
eukaryotic cells. The GI tract, due to its anatomy provides the largest inhabitable space. Bacteria 
residing in or GI tract are collectively known as the gut microbiota. Microbiome, on the other hand, 
describes all constituents of microbiota: genes, proteins and metabolites; which collectively influence 
an array of host's physiological processes. Our microbiome is often referred to as commensal bacteria, 
giving the impression that the bacteria and host have no influence over each other's physiology. 
However, this statement might underestimate the potential of the microbiota to influence host 
condition whilst host genetics can influence the composition and functions of its microbiota. Today we 
know that our bacterial communities contribute to many physiological processes taking place in the GI 
tract (39). These functions include breakdown of complex polysaccharides (40), conversion of 
conjugated bile acids (41) and production of vitamins B-1, B-2, B-12 and K (42). In this way the 
microbiota provide a set of metabolic traits, which are needed for our lives, but which we do not 
intrinsically possess. 
1.2.1 Development and composition of intestinal microbiota 
Foetus developing in the mother's uterus is believed to be free of bacteria. It does, however, remain 
under the influence of maternal microbiome. Delivery provides the first contact between bacteria-free 
neonate and bacteria-laden environment. The mode of delivery is important for the establishment of 
proper intestinal bacterial communities. Vaginally born children are first colonised by the maternal 
faecal and vaginal flora. Caesarean section delivery leads to disrupted colonisation of the gut in 
children, where the flora is acquired mostly from the skin of hospital stuff and the hospital 
environment (43–48). Colonisation of the infant's gut at birth seem to be important for proper energy 
extraction from milk, which is a new source of nutrients for the newborn. Certain bacterial species, 
especially Bifidobateria and Bacteroidetes thetaiotaomicron were reported to play a major role in the 
breakdown of milk oligosaccharides, which provides easily available energy source for the infant (49). 
The colonisation progresses gradually from birth throughout our entire life-span. During early 
childhood the number of bacteria inhabiting the gut is growing and changing dynamically. Aerobic 
and facultative anaerobic bacteria, which are the first gut colonizers are slowly replaced by obligate 
anaerobes. This process can be disrupted by the use of antibiotics, which may lead to permanent 
changes in the composition of intestinal flora and development of several diseases, including 
childhood obesity (50–53). Bacterial numbers and composition stabilises within 2-3 years from birth, 
reaching 10
12
 bacteria in one ml of faecal content. At this stage the infants microbiota resembles that 
of an adult individual. In general mammalian intestinal bacteria belong to nine phyla: Firmicutes, 
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Bacteroidetes, Actinobacteria, Proteobacteria, Verrucomicrobia, Cyanobacteria, Fusobacteria, 
Spirochaetes and TM7 (54). These phyla are represented by numerous bacterial species, of which only 
a very small proportion is shared by majority of individuals underlining the enormous diversity of 
mammalian commensal microbial community (55). In 2011 Arumugam and colleagues proposed to 
divide human microbiota into three functional groups (56). These groups were called enterotypes and 
the division was based on the functional characteristics of bacteria inhabiting the gut. Enterotype I, for 
example, is thought to be dominated by Bacteroidetes, which have the ability to ferment complex 
carbohydrates and synthesise biotin. Enterotype II would be dominated by Prevotella, which degrade 
mucins and other proteins (56). The presence of these two enterotypes was later confirmed in an 
independent study (57). Enterotypes seem also to be linked with long term dietary habits, 
distinguishing between meat eaters and vegetarians. Indeed, it seems that the environmental cues 
(including diet), rather than genetic factors, are responsible for the huge variation of bacterial 
composition amongst humans and other mammals (58,59). The concept of enterotypes requires further 
investigation in order to confirm its universality, but even now provides an interesting way of looking 
at functional groups and their role in shaping the physiological processes of the host, rather than single 
at the presence or absence of particular species of bacteria. While looking at the microbiota we must 
therefore consider not only the different species but also the genes that are carried by the bacteria 
which will be responsible for their function in the gut. There are 100 more bacterial open reading 
frames in our intestines than our own genes. The most abundant bacterial genes code for enzymes 
involved in the digestion of complex sugars and their fermentation to SCFA. 
Intestinal 
compartment 
Bacterial 
abundance (cfu/ml) 
Dominant bacteria 
Stomach 1-10
2 Lactobacillus, Streptococcus, Helicobacter, 
Peptostreptococcus 
Duodenum 10
1
 - 10
3 
Streptococcus, Lactococcus, Staphylococcus 
Jejunum 10
2 
- 10
4 
Lactobacillus, Streptococcus, Enterococcus 
Ileum 10
7
 - 10
9 
Segmented filamentous bacteria, Enterobacteriaceae, 
Bacteroides, Clostridium 
Colon 10
11
 - 10
12 
Bacteroides, Clostridium, Lachnospiraceae, 
Proteobacteria, Actinobacteria, Prevotellaceae, 
TM7, Fusobacteria, Verrucomicrobium 
Table 2. Spatial distribution and composition of the microbiota along the GI tract (60,61). 
1.2.2 Short chain fatty acids 
Short chain fatty acids (SCFA) are bacterial metabolites produced by anaerobic fermentation of dietary 
complex carbohydrates and proteins. There are three major SCFA produced in the gut: acetic acid, 
propionic acid and butyric acid. It is not uncommon for these acids to form salts with sodium in the 
colon, therefore they are often named: sodium acetate, propionate or butyrate respectively (Figure 2). 
SCFA are produced in millimolar concentrations. In mouse the concentration of SCFA reaches 10mM 
in the proximal small intestine and 40mM in the colon (62). The most abundantly produced SCFA is 
acetate, followed by propionate and butyrate (63). In human faeces the concentration of butyrate is 
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between 10-20mM. In mice the colonic concentration of butyrate vary between 0,5mM to 3,5mM (64). 
Butyrate is the main energy source for colonocytes (65). Butyrate can also be transported to the liver, 
where together with propionate and acetate it may become a substrate for lipogenesis (66,67). Acetate 
is also transported to the peripheral tissues and is detected in the blood stream at micromolar 
concentrations (68). Apart from being energy source for the host, SCFAs also regulate various cellular 
processes. SCFAs enter the cell by simple diffusion or by binding to various transport proteins on the 
cell membrane. Once inside the cells SCFAs work as histone deacetylase (HDAC) inhibitors. HDACs 
control the acetylation status of histones and many other proteins, including transcription factors and 
regulators, DNA repair enzymes, chaperon proteins and inflammatory mediators (69,70). Apart from 
their function as HDAC inhibitors, SCFAs also affect cellular processes before entering the cell. This 
signalling pathway is mediated mostly by binding of SCFA to G-protein coupled receptors, mostly to 
GPR41 and GPR43. Activation of these receptors by SCFA leads to secretion of peptide YY which 
slows down gastrointestinal transit. SCFA signalling via GPR 43 is also crucial in regulation of energy 
balance and adiposity of the host. Additionally SCFA may signal through GPR41 in other tissues, like 
adipocytes which leads to increased adipogenesis, decreased lipolysis and inducing leptin secretion 
(71). GPR43, on the other hand, is expressed on variety of immune cells including neutrophiles, 
eosinophiles and macrophages. Signalling via GPR43 on these cells is linked to anti-inflammatory 
properties of SCFAs.  
Figure 2. Schematic structures of sodium acetate (A), sodium propionate (B) and sodium butyrate (C). 
Generated with BioClipse 2.0. 
 
1.2.3. Interactions between the microbiome and the host 
The host and the microbiome co-evolved for millions of years to minimize the genetic pool and to use 
each other's genes and enzymatic functions in the most optimal way (72,73). The mammalian 
microbiome controls digestive function of the GI tract, immune responses (74), energy metabolism 
(75) and even behaviour (76–78). The presence of commensal microbiota inhibits the growth of 
pathogens. Microbiota can also metabolize toxins to less or more harmful substances contributing to 
the intestinal xenobiotic metabolism. They also produce a variety of biologically active substances like 
SCFAs, conjugated linoleic acid (CLA), phenoles, indoles, or trimethylamine (TMA) (79–81). 
Microbiota play an important role in preventing or accelerating development of lifestyle diseases like 
cancer, obesity or cardiovascular diseases (82). Maintenance of peaceful relationship between the 
microbiome and the host is therefore essential for health.  
The best model to study how bacteria influence host's physiology is the germfree (GF) mouse, which 
is devoid of bacteria. GF mice can be monocolonised with a specific bacterial species to assess the role 
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of this very species in the regulation of many physiological processes, including energy homeostasis. 
Whole bacterial community from conventionally raised mice (specific pathogen free, SPF) can also be 
introduced to GF mice, a process called conventionalisation. Colonisation of mice has profound 
effects on gene expression in host's cells. Processes in which microbiota play the most visible role are 
regulation of energy homeostasis, immune system regulation and activation of host defence systems.  
1.2.3.1 The microbiome and energy metabolism 
The most straight forward way to assess if the microbiome plays a role in energy metabolism, and as a 
consequence in the development of diet-induced obesity and metabolic disorders, is to compare the 
outcome of feeding of GF and SPF mice specially composed semi-synthetic diets with increased 
amount of fat. Several studies with such a design have been conducted with an overall conclusion that 
GF mice are protected from high-fat diet induced weight gain and insulin resistance (83,84). However, 
one other study suggests that this resistance is dependent on the composition of the diet and thus more 
investigation is needed in order to unravel the contribution of the intestinal microbiota to the 
development of obesity (85). Conventionalisation, i.e. introduction of a "normal" SPF microbiota to a 
previously GF mouse is another method to study the contribution of bacteria to regulation of metabolic 
processes and allows for studying the dynamic metabolic changes from the moment of introduction of 
microbiota to a given point in time (usually up to 14-30 days). Colonisation of GF mice results in 
increased body weight and adiposity. These effects are mimicked by the introduction only two 
bacterial species, namely Bacteroidetes thetaiotaomicron and Methanobrevibacter smithii. These two 
species have the ability to ferment carbohydrates to SCFAs (86,87). This discovery raised a question if 
SCFAs contribute to development of obesity in mice and humans. Many studies were conducted but 
no consensus is reached so far. Some results indicate association of SCFAs with increased body mass, 
some do not find this correlation, other show the opposite, i.e. that increased SCFA concentrations in 
the animals'  caecum or supplementation of diet with SCFAs results in lower body mass (61). A recent 
elegant publication on human subjects, trying to solve this conundrum, was performed on 
monozygotic twins discordant for obesity. In these twin pairs, one individual was obese, and the other 
one lean. Presence of bacteria producing SCFAs was associated with lean phenotype. Interestingly, the 
lean and obese phenotypes could be transferred to GF mice together with the "lean" and "obese" 
microbiome (88).  
Intestinal bacteria have also been shown to influence other processes connected with energy and 
nutrients metabolism and to play a role in the development of several metabolic diseases. Intestinal 
microbiota and their metabolites were shown, for example, to play a role in cholesterol metabolism 
and the development of non-alcoholic fatty liver disease (89–91).  
1.2.3.2 Bacteria and intestinal inflammatory diseases 
Bacteria that live in our intestine play an important role in modulating the balance between immune 
tolerance and host defence. Many mouse models have been developed to study in details the role of 
microbiome in the development and pathogenesis of intestinal inflammatory disorders (IIDs). The 
IIDs comprise both inflammatory bowel disease (IBD) and more acute, pathogen driven inflammatory 
conditions.  IBD is a complex disease comprising at least two subtypes with different pathologies, 
namely Crohn's disease (CD) and Ulcerative Colitis (UC). The causes of IBD are not well understood 
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but are believed to be a combination of genetic predispositions, bacterial dysbiosis and environmental 
factors. Pathogen-driven inflammatory disorders are easier to study in the sense that the cause of the 
disease in usually an infection with a specific pathogenic bacteria. The most commonly studied mouse 
models for acute inflammation involve infections with Citrobacter rodentium or Salmonella enterica 
subs. enterica serovar Typhimurium. Many mice strains are naturally resistant to these pathogens due 
to so called colonisation resistance. Colonisation resistance is a phenomenon where commensal 
bacteria residing the in gut provide protection against invasion of opportunistic pathogens. Antibiotic 
administration is required prior to infection in order to obtain intestinal inflammation resembling 
diseases observed in humans. The use of antibiotics diminishes the numbers of commensal microbiota 
and changes the prevalence of certain bacterial groups abrogating the colonisation resistance and 
making the mice more susceptible to the infection (224).  
The presence of commensal bacteria is also necessary for the proper development of mucosal layer, 
production of certain types of AMPs and proper functioning of the ILCs. De-regulation of these 
processes may lead to alterations in the composition of intestinal microbiota and development of IBD 
(17,30,92). This in turn will alter the prevailing microbiome, including soluble metabolites which can 
transverse the mucosa, and affect epithelial and lamina propria cells. Some of these metabolites can act 
as activators of host receptors, such as PRRs and transcription factors. Rapid changes necessary for 
host responses in recognition of a changing microbial environment are best countered by transcription 
factors, especially ones that are ligand-inducible. 
1.3. Ligand-activated transcription factors 
In order for the bacteria to have an impact on the host, bacterial signals need to be sensed by an 
eukaryotic cell. This is usually done by the PRRs, some of which are expressed at the cell surface. 
However, signals must be transmitted within the cell to cause a specific reaction, for example 
modulation of host gene expression or activity of enzymatic pathways. One such sensors are ligand-
activated transcription factors. These proteins have the ability to respond quickly to environmental 
signals and induce expression of a given group of target genes. Ligand-activated transcription factors 
are a large group of structurally unrelated proteins, but all activated by a ligand and able to induce 
gene expression in response to ligand binding. There are many transcription factors that work in a 
ligand-dependent manner and respond to environmental cues. This work focuses on two of them, that 
are especially important for intestinal physiology: Peroxisome proliferator-activated receptor gamma 
(PPARγ), belonging to the nuclear receptors family and Aryl hydrocarbon receptor (AhR) - a member 
of basic helix-loop-helix/PER-ARNT-SIM family. 
1.3.1 Nuclear receptors 
Nuclear receptors (NR) are a group of structurally-conserved ligand-activated transcription factors. In 
humans 49 members of the NR superfamily have been identified. Almost all NRs contain two 
activation domains, AF-1 and AF-2 of which one functions in a ligand-dependent manner and the 
other one in a ligand-independent way. AF-1 and AF-2 are separated by DNA-binding domain, a 
linking region and ligand-binding domain (Figure 3). These domains acquire a characteristic 
conformation upon ligand- and DNA-binding which allows for interaction with a set of co-factors 
(activators or repressors) as well as for homo- or heterodimerisation with other NRs. Depending on the 
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type of ligand, NRs are divided into three main classes. The first class includes the steroid- and 
thyroid-hormone receptors like oestrogen and glucocorticoid receptors. The second class consists of so 
called orphan receptors that share the structure and functionality of a typical NR but for which no 
naturally occurring ligand has been identified yet. It is also possible that no such ligand exists and that 
these receptors function in a ligand-independent way. The third class of NRs consists of so called 
adopted NRs, for which the natural ligands were discovered only recently. 
 
 
 
 
 
 
Figure 3. Schematic representation of NR protein domains. 
Green – activation domains (AF-1 and AF-2), blue – DNA binding domain composed of two zinc-
fingers based domains, red – ligand binding domain, gray – variable regions including hinge region 
linking the DNA-binding domain with ligand-binding domain. 
 
Upon ligand binding NRs bind specific DNA sequences and induce transcription of their respective 
target genes. By regulating gene expression, NRs control virtually all processes in our bodies, 
including reproduction, development, immune responses and metabolism. Based on NRs' expression 
patterns and functions of their target genes, NRs are divided into two main clusters (93). The first 
cluster contains NRs essential for the proper development of an organism and basic physiological 
functions. NRs assigned to this cluster are expressed in the reproductive organs controlling sexual 
maturation and function (oestrogen receptor, testosterone receptor). This cluster also contains NRs 
expressed in the central nervous system which controls neural development. Other members of this 
cluster are expressed in the liver and heart, and their function is coupled to circadian clock rhythms 
controlling for example cardiac function or cholesterol efflux to the liver. The second cluster contains 
NRs that are expressed mainly in the gastro/enterohepatic axis and key metabolic tissues (muscle, 
adipocytes). This cluster is divided into three groups with distinct functions: 
 bile acid and xenobiotic metabolism with function in nutrient uptake and barrier maintenance 
 lipid metabolism and energy homeostasis - use of dietary-derived lipids as fuel  
 lipid metabolism and energy homeostasis - specialised aspects of fuel utilisation like glucose 
homeostasis, lipid storage, cholesterol metabolism  
Nuclear receptors do not only induce the expression of target genes, they can also block transcription 
of certain subsets of genes, a phenomenon known as trans-repression. During infection pro-
inflammatory genes are often repressed by ligand-bound NRs. There are many models trying to 
explain the molecular basis of trans-repression. Two main mechanisms are postulated to explain this 
phenomenon: (i) activated NR prevents removal of repressive complexes from the promoters of pro-
inflammatory genes, or (ii) activated NR competes for transcriptional activators, which cannot be 
recruited to the promoters of pro-inflammatory genes (94,95). 
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1.3.2 Nuclear receptors co-regulators 
Nuclear receptors do not work alone but rather in combination with a battery of co-regulators. These 
co-regulators can enhance the function of a NR (co-activator, NCoA) or block it (co-repressor, NCoR). 
Co-activators play an important role in regulation of NR's function and fine-tuning of the target genes' 
expression levels. Co-activators recruit transcription machinery to the promoter allowing for 
chromatin conformation changes by acetylating or methylating histone tails. Co-repressors usually 
bind the non-liganded form of NR preventing its unspecific activation. Binding of a co-repressor to a 
liganded NR was also reported and probably plays a role in trans-repression of genes. NCoR have 
often histone deacetylase (HDAC) activities whereas NCoA functions often as histone acetyltrasferase 
(HAT) (96).  
1.3.3 Peroxisome proliferator-activated receptors 
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors 
belonging to the superfamily of nuclear receptors. PPARs were first discovered and cloned in the early 
1990s (97). Three forms or PPARs have been described so far: PPARα, PPARβ (also known as 
PPARδ) and PPARγ. In order to induce gene expression PPARs must form heterodimers with another 
NR, called Retinoic X Receptor (RXR). PPARs bind specific DNA sequences called PPAR response 
elements (PPREs), which are variation of a consensus sequence AGGTCA (98).  PPARs' ligand 
binding pockets are quite big and flexible allowing for attachment of various types of ligands, 
sometimes with quite different chemical structures including fatty acids, arachidonic acid, 
prostaglandin derivates and thiazolidinediones (TZD) (99–101). 
Each of the three PPARs has a specific tissue and cell type expression pattern as well as a set of target 
genes that determines its physiological function. PPARα is expressed in the gastrointestinal 
epithelium, liver, skeletal muscle and heart. It favours utilisation of lipids as energy source in those 
tissues (102). PPARβ is expressed virtually in all tissues and its exact function in each of them remains 
unknown. In the skin and intestine PPARβ plays an important role in wound healing, whereas in the 
skeletal muscle it regulates lipid metabolism. PPARγ has been most extensively studied as an 
important regulator of adipocyte maturation and lipid storage (103). However, PPARγ is expressed not 
only in the adipocytes, but also in other cell types.  
1.3.4 The functions of PPARγ 
PPARγ is activated by a variety of ligands, including unsaturated fatty acids (100), oxidised low 
density lipoproteins (oxLDL) (104), prostanoids like 15-deoxy-d-12,14-prostaglandin J2 (101) as well 
as synthetically obtained thiazolidinediones (TZD) (99). PPARγ is expressed as two isoforms: γ1 and 
γ2 which differ by 28 aminoacids in the AF-1 domain. The longer γ2 version is expressed almost 
exclusively in adipocytes. The shorter γ1 isofom is expressed by a variety of different cell types 
including immune system, skeletal muscle, bone building cells and epithelial cells of the 
gastrointestinal tract (105). 
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1.3.4.1 PPARγ and metabolism 
The most well known and most intensively studied function of PPARγ is its ability to regulate 
metabolic processes. PPARγ is necessary and sufficient for adipocyte differentiation (106) and 
regulates the storage or release of fat from the adipose tissue. PPARγ regulates also the production and 
secretion of hormones from adipose tissue, including lectin and adiponectin as well as other signalling 
molecules like Angiopoietin-like 4 protein (ANGPTL-4) a.k.a Fasting induced adipose factor (FIAF). 
PPARγ is also expressed in the brown adipose tissue (BAT), which has a function in maintaining body 
temperature via thermogenesis (107,108). Activation of PPARγ by TZD improves glucose and insulin 
tolerance in subjects with obesity and metabolic disorders. This effect might be mediated simply by 
instructing the adipose tissue to store and retain more fatty acids, which are otherwise toxic to the 
peripheral tissues. However, obesity and diabetes are not purely metabolic diseases. Many other 
factors including the aberrant activation of the immune system play a significant role in the 
development of these pathologies. Interestingly, activation of PPARγ in macrophages was partially 
responsible for the therapeutic effects of TZDs (109,110). 
 
1.4.4.2 PPARγ and immunity 
Although PPARγ has been studied predominantly as a regulator of energy metabolism the evidence for 
its importance as an immune regulator is growing. PPARγ is expressed in variety of immune cells, out 
of which the most well studied are macrophages and dendritic cells. Stimulation of macrophages with 
PPARγ ligands prevents expression of pro-inflammatory genes upon stimulation with MAMPs like 
LPS (111). These effects are believed to be due to trans-repression of Nuclear Factor κB (NFκB) 
target genes which may lead to development of so called alternatively activated macrophages (or M2), 
in which PPARγ is important for the maintenance of the anti-inflammatory properties.  The anti-
inflammatory properties of M2 macrophages are connected with PPARγ-induced metabolic changes in 
these cells (112,113). PPARγ activation in DC also induces expression of genes connected to lipid 
transport and metabolism. Activation of PPARγ enables lipid presentation by DC, which is needed for 
activation of invariant natural killer cells, which then secrete variety of cytokines (including IL-4 and 
IL-5).  
 
1.4.4.3 PPARγ in the intestinal epithelial cells 
PPARγ is highly expressed in the intestinal epithelial cells (IEC) (114,115). In the colon PPARγ is 
expressed in both differentiated cells and stem cells. In the small intestine PPARγ's expression is 
induced at the crypt/villus junction, where the epithelial cells start to differentiate (116–118). 
Activation of PPARγ in the GI tract can be achieved in many ways. Oral administration of TZD 
activates the receptor and induces expression of many of the PPARγ target genes, including that of 
ANGPTL4 (119). Activity of PPARγ can be modulated in vitro by bacteria and their metabolites 
(119–121). Activation of PPARγ in the IEC leads to elevated expression of specific target genes. 
Those target genes can be functionally divided in 4 major cluster controlling different physiological 
processes: (i) metabolism (mostly lipid transport and metabolism), (ii) cellular signal transduction, (iii) 
proliferation (withdrawal from cell cycle and differentiation), and (iv) cellular motility and adhesion 
(117).  
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Expression and activity of PPARγ in IEC is important for the maintenance of homeostasis between 
microbiota and the host.  Deletion of PPARγ results in decreased expression of defensins and reduced 
antimicrobial defences against infections caused by Escherichia coli and Bacteroides fragilis  in the 
colon (122). PPARγ protects also against experimentally induced colitis in mice (123–126). In 
humans, patients with IBD have lower expression of intestinal PPARγ then healthy people (127). 
Additionally several polymorphisms in the PPARγ gene were identified and associated with risk of 
developing the disease. The most commonly found polymorphism is observed at position 12 in amino 
acid sequence. The Ala12Ala genotype seems to protect against development of IBD in the European 
population (128) whereas the Pro12Ala allele was associated with increased risk of developing IBD in 
several studies (129–131).  
1.4.3 Basic helix-loop-helix/PER-ARNT-SIM proteins 
Basic helix-loop-helix (bHLH) proteins are transcription factors, as are nuclear receptors. Even though 
the functional properties of these two groups are similar, they have very different molecular structures. 
bHLH transcription factors posses two α-helixes linked by a loop which provides flexibility. Similarly 
to NR bHLH protein usually require dimerisation with other proteins in order to exert its function. The 
conserved DNA sequence to which bHLH proteins bind is called E-box and has a consensus sequence 
CANNTG. The PER-ARNT-SIM (PAS) proteins form a subgroup within bHLH transcription factors, 
making a group called bHLH/PAS proteins.  bHLH/PAS have two PAS domains, PASA and PASB, 
which are however poorly conserved in amino acid levels within the group. The structure of a typical 
bHLH/PAS protein is shown in Figure 4. The PAS domains provide specificity of action and influence 
the dimerisation properties of each protein. PASA domain prevents binding with bHLH proteins that 
do not contain a PAS domain. The presence of PASA also allows the transcription factor to bind non-
classical E-box sequences. PASB binds small molecules and provides interaction with other proteins 
that respond to metabolic or environmental signals (132,133).  There are 19 members of bHLH-PAS 
family with broad range of functions including regulation of developmental processes and response to 
stress. bHLH/PAS proteins can be divided into two classes. Class I is usually tissue restricted or signal 
specific. The members of class II are ubiquitously expressed and activated by a variety of stimuli. In 
order to bind DNA class I bHLH/PAS proteins dimerise with proteins from class II. The examples of 
class I bHLH/PAS proteins include: single-minded homolog 1 (SIM1) expressed in the neurons, 
ubiquitously expressed CLOCK (Circadian Locomotor Output Cycles Kaput) and stimuli-responsive 
hypoxia inducible factor 1 alpha (HIF1α) and aryl hydrocarbon receptor (AhR).  
bHLH/PAS proteins also bind a set of co-activators similarly to NRs. In most cases binding of the co-
factor enhances the expression of specific target genes. Additionally some co-regulators initially 
identified as NR co-activators have been shown to have a high sequence similarity to bHLH/PAS 
proteins and this domain allows them to interact with many proteins including p53 and signal 
transducer and activator of transcription 6 (STAT6). NCoA1 and 3 were shown to bind to AhR and 
aryl hydrocarbon nuclear translocator (ARNT) and modulate the activity of these receptors. 
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Figure 4. Schematic representation of bHLH/PAS protein domains.  
Green – bHLH domain responsible for DNA binding and dimerisation with other proteins, blue – PAS 
domains responsible for dimerisaton, red – transactivation domains, gray – variable regions 
1.4.3.1 Aryl hydrocarbon receptor (AhR) 
AhR is a ligand activated transcription factor that belongs to the bHLH/PAS family (134–136). The 
PASB domain of AhR provides interaction with heat shock protein 90 (HSP90). Other two chaperon 
proteins, namely p23 and AhR interacting protein (AIP) are also bound to AhR in the cytoplasm. AhR-
HSP90-p23-AIP complex remains in the cytoplasm and does not possess transcriptional activity. 
Within this complex AhR is in a conformation that exposes the ligand binding pocket (137). Upon 
ligand binding the conformation of the AhR changes exposing the DNA-binding domain and 
translocation of the AhR to the nucleus. In order to bind to DNA AhR needs to form a heterodimer 
with ARNT (138,139). The DNA binding specificity is provided by PASA domain.  
 
 
 
 
 
 
Figure 5. AhR as a ligand-
activated transcription factor 
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The consensus sequence TNGCGTG to which AhR-ARNT complex bind is called xenobiotic response 
element (XRE) or drug responsive element (DRE) (140). The mechanism of action of AhR as a 
transcription factor is depicted in Figure 5. Deletion of PASA domain of the AhR makes the protein 
non-functional, whereas deletion of PASB results in constitutively active AhR protein (141).  
1.4.3.2 The functions of AhR 
AhR is highly conserved evolutionarily and expressed in many cell types (142,143). AhR plays 
multiple roles in induction of metabolism of xenobiotics and regulation of physiological processes, 
including immune regulation and energy metabolism. Historically the most studied AhR target genes 
are Phase I drug metabolizing enzymes CYP450 family members: CYP1A1, CYP1A2 and CYP1B1, 
inducing the detoxification cascade (144).  The prototypic AhR ligands include man-made pollutants, 
2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD), 3-methylcholanthrene (3MC), benzo(a)pyren and other 
polycyclic aromatic hydrocarbons  (145). Activation of AhR by those ligands leads to several toxic 
effects including  alterations in lipid metabolism, and embryonic development as well as 
tumorigenesis and immunosuppression (146). In recent years, however, a battery of natural AhR 
ligands has been discovered, including  metabolites or derivates of tryptophan, like FICZ (6-
formylindolo[3,2-b]carbazole) or kynurenine as well as other dietary ligands, like indole-3-carbinol 
(I3C), present in cruciferous vegetables, such as broccoli and cauliflower (147–149). Activation of the 
AhR by these naturally-derived ligands was shown to have physiological effects, sometimes opposite 
to the ones caused by the environmental pollutants (150–152). Apart from its function as a 
transcription factor AhR has also been shown to act as a E3 ubiquitin ligase and may in this way 
regulate the stability of the oestrogen receptor (153).  Deletion of AhR results in a variety of 
immunological, metabolic and developmental defects. One of the most striking feature of the AhR KO 
mice is liver deformation caused by a failure to close the ductus venosus (a blood vessel shunt in the 
liver) after birth leading to lifelong impairment of blood flow in the liver. As a consequence, the liver 
of an AhR KO mouse is roughly half the size of a liver of a WT mouse (154). 
1.4.3.3. AhR and immunity 
Apart from being a metabolic regulator, AhR also plays an important role in modulating the functions 
of the immune system and response to bacterial infections (reviewed in (155)). AhR is especially 
important in the regulation of development and function of dendritic cells and T-cells, including T 
helper cells (especially Th17) and Treg cells. Treg cells play a crucial role in the distinguishing 
between self and non-self and development of tolerance. AhR is very important in the induction of 
expression and stability of the transcription factor FoxP3, which promotes the differentiation of T cells 
into Tregs. AhR is also important for the development and functioning of Tr1 in the colon. Both Treg 
and Tr1 produce the anti-inflammatory IL-10, a process which is most probably AhR-dependent. 
Apart from being a direct regulator of T cell development, the AhR is also involved in generation and 
activity of DCs. DCs on the other hand influence differentiation of T cells to a variety of subtypes, 
including Th17, Treg and Tr1 cells. AhR decreases the ability of DC to present antigens and inhibits 
secretion of T-cell stimulatory cytokines. In this way, the AhR indirectly promotes the development of 
Treg and Tr1 cells, rather than Th17 cells. AhR increases the expression of IDO (idoleamine 2,3-
dioxygenase) in DCs. This results in production of kynurenine which is immunosuppressive. 
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Kynurenine may in turn activate AhR in T-cells which promotes the development of Treg cells. One 
another AhR-dependent process is the production of retinoic acid by DCs. Retinoic acid is required to 
promotes the differentiation of Treg at mucosal surfaces. 
1.4.3.4 AhR in the GI tract 
AhR is an important payer in maintaining the intestinal homeostasis. It is required for development of 
intraepithelial lymphocytes (IEL) and innate lymphoid cells producing IL-22 (ILC22). AhR KO mice 
are more susceptible to chemically and bacterially induced colitis (34,150,205-209). Lymphocytes 
taken from patients with CD have decreased expression of AhR. In experimental animal models, 
activation of AhR resulted in amelioration of disease and decreased inflammation. However, these 
studies had very limited potential for translating into humans because the AhR's ligands used (like 
TCDDs or benzo(a)pyren) have very high toxicity (156). Only the recent discovery of endogenous or 
food-derived AhR ligands opened new horizons for treatment of inflammatory conditions by 
activating AhR. Indol-3-carbinol (I3C) is a component of dietary vegetables that is known to activate 
AhR in vivo and to provide a signal to retain the IEL in the gut, which gives protection against the 
intestinal inflammation (151). AhR expression in ILC is critical to protect the mice against Citrobacter 
rodentium infections, as mice lacking the AhR are much more susceptible to infection (157). Apart 
from the role of AhR in modulation of function of IEL and ILC22, AhR blocks the development of 
Th17 cells and promotes that of Tr1 during experimentally-induced colitis (158). In parallel to 
nutritionally-derived anti-inflammatory AhR ligands, bacterial signals also ameliorate colitis in mouse 
models in a potentially AhR-dependent manner. More studies, especially clinical trials with humans 
are needed to fully appreciate the role of AhR in the function and protection of the gastrointestinal 
tract. 
 
1.4.3.5 AhR and metabolism 
The role of AhR in metabolism has been studied almost exclusively in conjunction with toxicity of 
man-made pollutants on animal models. Chronic administration of TCDD to mice results in profound 
changes in expression of genes regulating cholesterol synthesis, de novo lipogenesis and glycolisis 
(159). Acute exposure to TCDD lowers the expression of genes involved in gluconeogenesis in the 
liver (160) and decreases glucose transport into the adipose tissue (161). Administration of 3MC in 
C57Bl/6J mice resulted in fat accumulation in the liver and development of liver steatosis in 
conjunction with increased levels of PPARα mRNA (162). Transgenic mice expressing constitutively 
active AhR in the liver and intestine develop hepatic steatosis as well (163). On the other hand 
deletion of the AhR results in lower expression of PPARα and decreased expression of genes, whose 
protein products are involved in β-oxidation of fatty acids (164). All these studies indicate a strong 
link between AhR expression/activity and metabolism of fats and glucose, mainly the regulation of 
gluconeogenesis and β-oxidation of fatty acids.  
The only evidence of involvement of the AhR in regulation of metabolic processes in human comes 
from epidemiological studies. Studies have indicated a correlation between global obesity epidemic 
world-wide and the increasing exposure to environmental pollutants, which are potential AhR ligands. 
The presence and concentration of many of these pollutants in human serum is positively correlated 
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with diabetes and metabolic syndrome (165). A recent study also links circulating serum AhR-ligands 
with mitochondrial dysfunction (166). Additionally, many of the these substances have oestrogen-like 
properties and exposure to these leads to disturbed hormonal balance and metabolic problems. This 
problem is of particular importance because AhR may directly and indirectly interact with oestrogen 
receptor itself (153).  
In summary we can say that some small molecules (of dietary or microbial origin) may function as 
ligands for the ligand-activated transcription factors. These factors, including PPARγ and AhR would 
then bind to their respective response elements on the DNA and induce expression of their specific 
target genes. In this work we have focused on two main groups of target genes, which play a role in 
modulation of inflammation and metabolism. By regulating transcription of these two functional 
categories of genes the ligand-activated transcription factors regulate the function of the GI tract, liver 
and muscle (summarised in Figure 6) 
 
 
 
 
Figure 6. Small molecules can act as 
agonist to trigger ligand-activated 
transcription factors, which execute 
various functions in organs such as 
the intestine, liver and muscle. 
 
 
 
1.5 Liver and the control of energy metabolism 
Liver is traditionally not included in the concept of the GI tract. However, one should not forget the 
connection of this organ to the functioning of the GI tract. Liver is directly connected to the small 
intestine by the hepatic portal circulation. Hepatic portal vein transports nutrients, toxins and 
signalling molecules absorbed in the intestine directly to the liver, where they can be stored or 
metabolised before reaching the general circulation. Liver is therefore the first target organ for the 
intestinal signals and a sensor of intestinal health.  
Liver is also one of the main organs responsible for the regulation of the host energy balance and 
metabolism. During fasting periods lipids are liberated from adipose tissue to the blood stream in form 
of glycerol and free fatty acids (FFA). FFA are taken up by the liver by various fatty acid transporters,  
including CD36 (167,168) and fatty acid binding protein 1 (FABP1, a.k.a. L-FABP) (169,170). Once 
inside the cell, FFA are activated by the Acyl-CoA synthetase which adds a Coezyme A (CoA) 
molecule to FFA generating Acyl-CoA. The fate of Acyl-CoA depends on its carbon chain length. 
Very long (>20C) and long (C14-20) acyl-CoA molecules are directed primarily to peroxisomes. 
However, it was shown that in brown adipose tissue the medium chain fatty acids can also be oxidised 
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inside peroxisomes (171). The first reaction of β-oxidation (desaturation) inside peroxisomes is 
catalysed by Acetyl-CoA oxidases (ACOX) that donate electrons directly to molecular oxygen, 
thereby producing hydrogen peroxide that is later disposed of by catalase.  (172). Long, medium and 
short chain fatty acids are oxidised in the mitochondria. If the mitochondrial β-oxidation pathway is 
compromised medium and short chain fatty acids may be oxidazied in the endoplasmatic reticulum by 
enzymes belonging to the Cytochrome P450 family, like CYP4A1. Short and medium chain fatty acids 
enter the mitochondria by simple diffusion, but long chain fatty acids depend on a transportation 
system involving carnitine palmitoyl transferases (CPT1 and CPT2) and carnitine-acylcarnitine 
translocase (CACT a.k.a. Slc20a25) proteins. These proteins convert Acyl-CoA to acylcarnitine and 
then back to acyl-CoA inside the mitochondrial matrix in order to move the fatty acid molecule 
through the double mitochondrial membrane. The first step in the β-oxidation pathway inside the 
mitochondria is catalysed by chain length specific acyl-coA dehydrogenases: very long chain 
(VLCAD), long chain (LCAD), medium chain (MCAD) or short chain (SCAD) acyl-CoAs 
dehydrogenases. These Acyl-CoA dehydrogenases remove two carbons from the C-terminus of the 
acyl-CoA in each reaction and the process is repeated until acyl-CoA is degraded to two carbon atoms 
Acetyl-CoA molecule  (for Acyl-CoA with even numbers of carbons) or a three carbon atoms 
propionyl CoA (for Acyl-coA with odd number of carbons) (173). Propionyl Co-A is used as a 
substrate for gluconeogenesis whereas Acetyl-CoA can either enter the citric acid cycle (TCA) to be 
fully oxidised to CO2, or serves as substrate for ketone bodies synthesis. There are two main ketone 
bodies synthesised in the liver: acetoacetate and 3-hydroxybutyrate. Acetoacetate is produced in the 
liver in HMG-CoA cycle catalysed by acetoacetyl-CoA thiolase (ACAT1), HMG-CoA synthase 
(HMGCS2) and HMG-CoA lyase (HMGCL). Acetoacetate can then be reversibly transformed to  
3-hydroxybutyrate by D-3-hydroxybutyrate dehydrogenase (BHD1). Ketone bodies diffuse into the 
blood stream and are taken up by peripheral tissues, like the brain and skeletal muscle. In these tissues 
ketone bodies are converted back to Acetyl-CoA before they can be utilised as energy source and 
oxidizaed to CO2. This step catalysed by BHD1 (converting B-hydroxybutyrate to acetocetate), 3-
oxoacid CoA-transferase (OXCT1) and ACAT1. Brain tissue cannot oxidise fatty acids present in the 
blood, it therefore depends in a big part on the energy delivered in a form of ketone bodies during 
periods of low blood glucose levels caused by food shortage. Skeletal muscles are more flexible in the 
source of energy they use for proper functioning. Apart from ketone bodies skeletal muscle cells can 
directly use circulating fatty acids or glucose to gain enrgy. Based on the preference for utilizing 
glucose or fatty acids muscles are divided into two main types: white (where anaerobic glycolysis 
predominates) and red where β-oxidation of fatty acids take place. Both types can use ketone bodies as 
energy source during fasting periods. Lactate is a main product of glycolysis and an increased level of 
lactate in the plasma is an indicator of ongoing glycolisis.  
In this thesis I have perused the question as to whether the intestinal microbiome can either directly or 
indirectly influence the metabolic processes activated during periods of stress, such as  fasting. We 
know from the work of others that bacteria can regulate adipose tissue, liver and brain function 
(Figure 7).  Some of these effects may be mediated by metabolites potentially linked to the 
composition of the microbiota. Variations in the microbiome may confer different levels of 
adaptability to different kinds of metabolic stress.   
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Figure 7. The microbiome is thought to 
influence metabolic processes in  a variety 
of organs. Signals from the intestine can 
impact on both sides of the energy equation: 
energy harvest and storage in organs such 
as liver and adipose tissue, balanced against 
energy usage in e.g. brain and muscle. 
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2. AIMS  
The objective of this thesis was to investigate the interactions between the host and its intestinal 
microbiota. First of all, we were interested to see how intestinal bacteria, both commensal and 
pathogenic influence the expression and activity of two ligand-activated transcription factors PPARγ 
and AhR. Secondly, we set out to investigate the role of these receptors in sensing the bacterial signals 
and responding to them by regulation of expression of genes involved in metabolism and/or immune 
response.  
 
Specific aims for each paper: 
I. To evaluate the role for epithelial PPARγ in defence against Salmonella Typhimurium infection 
II. To investigate if the expression of ANGPTL4 in the intestinal epithelial cells is regulated by 
bacteria and their metabolites - short chain fatty acids and if this regulation was mediated via 
activation of PPARγ  
III.  To study the cross-talk between gut microbiota and AhR and its role in the regulation of 
energy metabolism. This paper has three specific aims: 
a. To study the impact of microbiota and its metabolites on the expression and activity of 
the AhR in the intestinal epithelial cells.   
b. To assess if absence of AhR influences the composition of intestinal microbiota 
c. To evaluate the role of the AhR in regulation of energy metabolism, in particular on 
glucose and fat utilisation during fasting 
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3. METHODOLOGICAL HIGHLIGHTS 
3.1 IEC-specific PPARγ knock-out  
In order to investigate the role of PPARγ on development of Salmonella-induced colitis we have used 
a mouse model, with non-functional PPARγ in IEC. These mice were generated by crossing two 
mouse strains. The first, called PPARγ-flox was a strain where the exon 2 of  PPARγ DNA sequence 
was flanked from the 3' and 5' ends by two LoxP sequences. The second mouse strain was a transgenic 
mouse that expressed Cre gene under the control of villin promoter. Villin promoter is 
transcriptionally active in the epithelial cells of the GI tract but not in any immune cell type, which 
allows for IEC specific expression of Cre. Cre is an endonuclease that recognizes and cuts LoxP DNA 
sequence generating double strand breaks at both ends of the region flanked by LoxP sequences. 
Crossing the Villin-Cre mouse to PPARγ-flox mice (F0) gives rise to mice (F1) in which Cre, 
expressed in IEC, generates double strand breaks at both ends of exon 2 of PPARγ gene. As a result of 
Cre-mediated DNA recombination the two LoxP sites are linked together omitting exon 2 of the 
PPARγ gene generating a frame shift, resulting in non-functional PPARγ. However, F1 mice have 
only one PPARγ allelflanked by the LoxP sites, the second one being a wild type allel, which not be 
targeted for Cre-mediated recombination. F1 mice are therefore back-crossed to PPARγ-flox mice in 
order to obtain a mouse with two allels with PPARγ LoxP sites and a Cre transgene (F2), which are 
than selected for further breeding. F3 provides mice with IEC specific PPARγ deletion (named PPARγ 
IEC KO or Cre+) and control mice (named PPARγ IEC LoxP or Cre-). The breeding scheme is shown 
in Figure 8. The presence or absence of Cre transgene as well as the deletion or PPARγ can be 
confirmed by PCR to allocate mice to KO or WT group. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Breeding scheme for obtaining PPARγ IEC specific knock-out as described in the text. 
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3.2 Gnotobiotic mouse models 
Gnotobiotic animals are a powerful tool to study the host-bacterial interactions and their physiological 
importance. A gnotobiotic animal (from Greek gnotos = known and bios = life) is an animal in the 
which microbial composition is known. In practice, the gnotobiotic animals can be completely devoid 
of bacteria - GF, containing only a single bacterial species - monocolonised or have several different 
species whose identity is known. GF, mono- and bicolonised mice have been used to assess the role of 
the microbiota in many processes including immune system development and resistance to infections, 
development of the gastrointestinal tract, energy metabolism with special attention to obesity and 
metabolic disorders, and recently signalling between the gut and the brain as well as behaviour.  
Maintenance of gnotobiotic animals requires special precautions and specific conditions, so that the 
animal cannot be colonised by unwanted microorganisms. In order to do this, gnotobiotic animals, 
mostly mice and rats, are kept in specially designed sterile isolators where all the incoming air is 
sterile filtered. Cages, bedding, and other housing materials as well as water and food must be 
autoclaved before given to the animals.  
Rearing a new strain of mice into GF conditions is based on a principle that pups in the uterus remain 
sterile and do not have direct contact with microorganisms and is done by transferring the pups while 
still within in the uterine sac to a GF foster mother. Even though the pups reared in this way and raised 
inside an isolator are considered GF one must remember that their mother was not, which means that 
they remained under microbial influence during in utero development. At least one or two generations 
of mice born in strictly GF conditions inside the isolators must pass before starting any experiments.  
Most GF  strains are viable and healthy, if certain vitamins, e.g. vitamin K and B vitamins are 
supplemented with food. The most characteristic feature differentiating a conventionally raised mouse 
from a GF mouse is that GF mice have enlarged caecum, most probably containing the undigested 
fibres and carbohydrates. Most  mouse strains breed normally under GF conditions. They do however 
have many developmental irregularities. Many of these are directly connected to the development and 
functioning of the GI tract, including altered vascularisation and muscle wall thickness (174). 
Expression of many of the NR and xenobiotic metabolizing enzyme is also disrupted in GF mice 
(175,176). Experiments performed on GF mice show that bacteria play a major role in the 
development of the hosts defence systems, including structure of mucus, production of AMPs by 
enterocytes, cytokines and immunoglobulins, which is diminished in mice lacking microbiota 
(15,177). All these features make GF mice more susceptible to infections with pathogens. However, 
GF mice seem to be resistant to certain inheritable chronic inflammatory diseases, underlining the 
importance of microbiota in development of immune system and responses (178). 
3.3 Metabolomics 
Metabolomics, together with genomics, transcriptomics and proteomics form the holistic way to look 
at an organism and all the biochemical processes that take place in it. The "omics" research exploded 
at the end of the last century due to huge technological advances allowing for processing hundreds, 
thousands or even millions samples in a very short time. Genomics aims to obtain a full DNA 
sequence of a given organism, transcriptomics studies the pool of genes transcribed to RNA, 
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proteomics the pool of mRNA translated into proteins. Metabolomics is the study of the metabolome. 
The metabolome is a collection of metabolites, especially small molecules that are present in a cell, 
tissue or other biological sample (usually blood or urine) under particular circumstances and are 
products of enzymatic reactions ongoing in the body. Metabolomics, therefore, allows getting a direct 
insight into which chemical and/or enzymatic processes are active at the given moment in the 
organism providing a functional readout of cellular state. Another advantage of metabolomics is that 
many biofluids like urine or blood can be analysed without any pre-treatment. For solid tissues, pre-
treatment usually confers separation of organic and aqueous phases prior to screening and analyses of 
these fractions separately. The most commonly used method in metabolomic screening in nuclear 
magnetic resonance (NMR). NMR consists of placing the sample of interest in a magnetic field, where 
the atoms, when excited by the field, produce a characteristic signal depending on the mass and 
structure of the chemical molecule. 
1
H-NMR methods are based on recording signals produced by 
atoms of hydrogens. These will generate spectra where hydrogen atoms in each molecule generate a 
specific signal. One molecule might therefore emit several signals, depending on the placement and 
bonding of hydrogen. The emitted spectra are then compared with standard spectra for each metabolite 
to generate the metabolite profile of a given sample. There are two main approaches for analysis of 
samples in metabolomic studies: targeted and un-targeted screenings. In targeted metabolomics only a 
small spectrum of metabolites of interest  is recorded and analysed. This approach is used mainly for 
screening for drug bi-products, or indicators of certain physiological processes, in which the 
metabolites of interest are known in advance. In un-targeted metabolomics the aim is to obtain the 
broadest spectra of metabolites and identify as many metabolites as possible. The spectra obtained in 
this way are usually used to compare the metabolic signatures between groups of individuals, for 
example healthy and diseased people, patients taking an active drug or a placebo. Such comparison 
allows for discovery of biomarkers for diseases. It also indicates which metabolic process are 
important for a particular pathophysiological state, which might later be used in a drug-discovery 
process.                       
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4. RESULTS AND DISCUSSION 
In this thesis I set out to get an insight into possible bidirectional interactions between the microbiome, 
composed of both commensal and potentially pathogenic bacteria, and the host. In order to study these 
complex interactions we have selected short chain fatty acids, as a model of a bacterially-derived 
product with known beneficial effects on host's health. From the host's side we have focused on two 
ligand-activated transcription factors known to be important regulators of metabolic and immune 
processes - PPARγ and AhR. 
4.1 Paper I: Absence of intestinal PPARγ aggravates acute infectious colitis in mice through a 
lipocalin-2-dependent pathway 
Salmonella enterica serovar Typhimurium (S. Typhimurium) is a Gram-negative, food-borne, 
pathogenic bacterium causing intestinal inflammation in humans. S. Typhimurium is also a model 
organism for studying bacterial virulence factors and invasion mechanisms. Animal models have been 
developed in order to study the pathology of Salmonella-driven colitis. However, mice infected with  
S. Typhimurium tend to develop systemic typhiod fever syndromes rather than intestinal 
inflammation. This phenomenon is most probably caused by colonisation resistance, the protective 
effects of intestinal flora preventing the out-growth and invasion of the pathogen. Pre-treating mice 
with an antibiotic streptomycin prior to S. Typhimurium infection is needed for the development of 
colitis that resembles human salmonellosis. Administration of the antibiotic leads to marked reduction 
of normal intestinal microbiota (up to 90%), which allows for the out-growth of Salmonella and 
development of a full-blown colitis within 24 hours from infection. For this reason S. Typhimurium 
infection is also used as a model to study the role of commensal bacteria in providing the host 
protection against the pathogenic invasion.  
In this paper we have investigated the role of PPARγ expressed in the IEC in the protection against 
Salmonella invasion and regulation of Salmonella-driven colitis. We showed that PPARγ protects 
mice against S. Typhimurium-induced colitis and tissue damage. During S. Typhimurium infection 
PPARγ expression levels drop in the IEC which results in increased expression of pro-inflammatory 
cytokines and anti-microbial peptides, amongst them LCN2. LCN2 is at least partially responsible of 
inducing the colonic tissue damage upon S. Typhimurium infection. 
4.1.1 PPARγ expression in the intestinal epithelial cells protects mice against colitis caused by 
Salmonella Typhimurium infection 
Expression and activity of PPARγ in the IEC seems to play an important role in the development of 
defence mechanisms against bacterial invasion and development of intestinal inflammation. PPARγ 
plays an important role in modulating the anti-inflammatory signals during infections. Deletion of 
PPARγ results in increased susceptibility to bacterial infections and chemically induced colitis (122–
126). On the other hand expression of PPARγ was shown to be lower in patients with IBD in one 
study (127). However, the role of PPARγ in S. Typhimurium-triggered colitis remained unknown. We 
first set out to investigate if  infection of mice with this pathogen has any influence on the expression 
of PPARγ. Indeed the expression of PPARγ was reduced in the caecal and colonic epithelium of mice 
infected with  S. Typhimurium. To make sure that the reduction of PPARγ expression is a direct effect 
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of Salmonella executed in the IEC we used an in vitro system, where colonic epithelial cell line was 
co-cultured with S. Typhimurium. The mRNA levels of PPARγ in Salmonella-exposed cells was 
lower than in mock-treated cells, indicating that the presence of immune cells in not necessary for the 
decrease in expression levels of PPARγ in IECs. There are reports suggesting interactions between 
pathogenic bacteria and PPARγ. Helicobacter pylori and Mycobacterium tuberculosis were shown to 
up-regulate the levels and activity of PPARγ in order to induce anti-inflammatory signals and prevent 
the release of cytokines and anti-microbial peptides (179,180). In the case of Salmonella many reports 
show that this pathogen needs the full-blown inflammation within the gut in order to have a survival 
advantage compared to normal commensal microbiota. S. Typhimurium, by down-regulating PPARγ 
expression induces anti-microbial responses, to which S. Typhimurium is resistant, which change the 
microbial composition and provide conditions for it to grow. 
Further on, we investigated if the downregulation of PPARγ in IEC is important in the pathogenesis of 
Salmonella-induced colitis. In order to do that we used the IEC-specific PPARγ knock-out mice. The 
Cre+ mice, which do not express PPARγ in the IECs were more susceptible to Salmonella infection. 
Cre+ mice had smaller caecum and shorter colons than Cre- mice. The activity of pro-inflammatory 
transcription factors, NFκB and AP-1 as well as the expression of pro-inflammatory cytokines were all 
higher in the infected Cre+ mice than in their Cre- siblings. The observation of increased pro-
inflammatory signals in the absence of PPARγ is probably due to trans-repression mechanisms 
described for PPARγ- NFκB interaction upon pro-inflammatory stimulation (111). Other mechanisms 
might also play a role in upregulation of pro-inflammatory signals in the PPARγ IEC KO. PPARγ 
regulates expression of trefoil factor 3 (TFF3), which is necessary for epithelial restitution and 
mucosal integrity promoting mucins cross-linking (181,182). It is therefore possible that PPARγ IEC 
KO has disrupted mucosal layer, which on the other hand disrupts intestinal homeostasis and 
predisposes the mice to S. Typhimurium - induced colitis. It seems therefore that intestinal epithelial 
PPARγ provides a level of protection against the full-blown inflammation in the colon. This 
observation is in accordance with other reports, showing that PPARγ expression and activity 
ameliorates chemically induced colitis (125,126,181).  
4.1.2 PPARγ regulates LCN2 
Deletion of PPARγ in IEC resulted in upregulation of expression of IL-17 and IL-22 in response to  
S. Typhimurium infection. These two cytokines are necessary for the production of AMPs by IEC. 
Antimicrobial peptides are important defence molecules that limit the invasion of intestinal pathogens 
and their expression is induced upon pathogenic infection. Indeed the expression of two AMPs: Reg3γ 
and LCN2 was induced upon S. Typhimurium infection, and their expression was much higher in the 
epithelial cells of in the PPARγ IEC KO. In order to investigate if the deletion of PPARγ had a direct 
effect on the expression of LCN2, or rather it was just due to increased intestinal inflammation we 
have used our in-vitro model. Knock-down of PPARγ by siRNA in HT-29 resulted in increased 
expression of LCN2, even without co-culturing of the cells with Salmonella. The level of LCN2 was 
increased in HT-29 following co-culturing the cells with Salmonella, and the effect was stronger in 
cells in which PPARγ expression was lowered by siRNA. The finding that LCN2 levels increase in 
response to Salmonella was surprising because it is resistant to LCN2 effects. The resistance of 
Salmonella to LCN2 is due to the fact that Salmonella uses another iron-chelating system, called 
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salmochelin, which does not bind to LCN2. Instead of reducing the growth of Salmonella, LCN2 is 
likely blocking the iron transport systems of commensal bacteria, causing a growth advantage for 
Salmonella (183–185). If that is the case then increased levels of LCN2 would favour the growth of 
Salmonella in the gut of PPARγ IEC KO mice. However, in our study we did not observe any 
differences in the numbers of S. Typhimurium cells between Cre+ and Cre- mice. What we observed 
was increased tissue damage in the PPARγ KO mice upon Salmonella infection. It therefore occurred 
to us that LCN2 might somehow contribute to the intestinal damage, which we investigated in the last 
part of the paper. 
4.1.3 LCN2 activity causes intestinal damage upon Salmonella infection 
LCN2 is a multi-functional protein, secreted to the intestinal lumen where it functions as an AMP 
sequestering iron and hindering bacterial growth, in this way preventing invasions of pathogens. 
LCN2 is also able to bind and stabilize matrix metalloproteinase 9 (MMP-9) in the intestinal lamina 
propria (186,187). MMPs play an important role in the remodelling of intestinal tissue by regulating 
the extracellular matrix turnover. MMP-2 and MMP-9 are associated with colitis. Expression of 
MMP-2 and MMP-9 is higher in patients with IBD. MMP-2 and MMP-9 have opposite functions: 
MMP-9 mediates tissue injury during colitis, whereas MMP2 maintains the gut barrier and protects 
against tissue damage. MMP-9 expression is low in normal colonic mucosa and is induced during 
colitis caused by administration of DSS or during S. Typhimurium infection. S. Typhimurium was 
shown to stimulate secretion and activation of MMP9 from macrophage via its surface protease PgtE 
(188). MMP9 KO mice are protected against colitis and tissue damage (189,190). Additionally 
activation of PPARγ by TZD results in lowered secretion of MMP9 from LPS-activated macrophages 
(191). We have observed an increased protein levels and activity of MMP9 in Cre+ mice infected with 
S. Typhimurium, whereas the level and activity of MMP-2 did not differ between Cre+ and Cre- mice. 
Additionally, we detected the LCN2-proMMP9 complex in protein extracts from the colon of mice 
infected with S. Typhimurium. This complex was present in larger amounts in the samples isolated 
from Cre+ mice in comparison to Cre- mice.  
To further investigate if the increased levels of LCN2-MMP9 complex had a deteriorating impact on 
colonic tissue integrity we used a LCN2 KO model. LCN2 KO mice were protected against S. 
Typhimurium-induced colitis and exhibited reduced colon shortening and tissue damage. Additionally, 
LCN2 KO mice in comparison to wild type mice had slightly higher levels of proMMP-9 protein, but 
not its activity upon infection with S. Typhimurium. Secreted MMP-9 was also detected in S. 
Typhimurium treated LCN2 KO mice, but to a much lesser extent that in PPARγ IEC KO mice. We 
observed similar dowregulation of PPARγ expression following S. Typhimurium infection in LCN2 
KO and wild type mice. There was also no difference in the levels of pro-inflammatory cytokines or 
Rag3 expression. These observations indicate that LCN2 expression plays a major role in mediating S. 
Typhimurium-induced tissue damage but does not influence the levels of PPARγ or pro-inflammatory 
signals. We speculate that blocking LCN2 would result in amelioration of colitis due to decreased 
tissue damage. This might be an important therapeutic strategy to reduce severity of intestinal 
inflammation because LCN2 seem not to affect the beneficial activity of over-all beneficiary MMP2. 
Blocking of LCN2 might therefore lower the stability and activity of MMP9 without influencing the 
function of MMP2.  
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4.1.4 Downregulation of PPARγ and the subsequent increase in LCN2 expression upon 
Salmonella-infection is TLR4-independent. 
In Paper I we show that S. Typhimurium down-regulates the expression of PPARγ in the IEC. We also 
show that deletion of PPARγ results in increased levels of LCN2, which in turn causes an increase 
activity of MMP-9 resulting in damage of the colonic tissue. The mechanisms by which  
S. Typhimurium exerts these effects remain unknown. Salmonella is a Gram-negative expressing 
various MAMPs on its cell surface, including LPS. LPS binds to and activates TLR4, which in turn 
initiates the signalling cascade activating NFκB transcription factor and induces expression of pro-
inflammatory cytokines. A previous report has shown that the PPARγ protein levels dropped upon 
exposure of macrophages to LPS in TLR4 dependent manner (192). We have therefore investigated if 
the effects of Salmonella on PPARγ expression could be attributed to activation of TLR4. We have 
used TLR4-deficient mice to test that hypothesis. Upon infection with Salmonella we observed a 
similar reduction in the PPARγ mRNA levels in TLR4 KO mice and in wild type mice.  Salmonella-
induced downregulation of expression of PPARγ appears therefore to the independent of TLR4 
signalling. Additionally, we compared the effects of S. Typhimurium and LPS on the expression of 
LCN2 and PPARγ in an in vitro model. LCN2 was increased and PPARγ expression decreased after 
co-incubation of cells with Salmonella. LPS had no effect on expression of LCN2 or PPARγ, it did 
however induce expression of IL-8, proving that the cells were responsive to LPS (Figure 9) 
 
 
 
 
 
 
 
 
Figure 9. Expression of IL-8, LCN2 and PPARγ in HT-29 cells co-cultured with Salmonella 
Typhimurium or LPS. Cells were exposed to treatments for 6 hours, after which they were washed with 
RPMI-medium and cultured in no-treatment containing medium for 18 hrs. Expression level of genes 
was analysed by qPCR and normalised to β-actin. Statistics: Students-t-test *, p<0,05; ***, p<0,001, 
against the control 
Other TLRs might be involved in the recognition of Salmonella and mediating its effect on PPARγ 
expression. Some other MAMPs present on the cell surface of S. Typhimurium include amyloids (curli 
fibrils), which binds to TLR2 and flagella, recognised by TLR5 (193–195). It is therefore possible that 
these TLRs are also responsible for initiating the signal transduction pathways leading to 
downregulation of PPARγ expression in the IEC. This question remains un-answered in Paper I.  
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It would however be interesting to investigate which, if any, TLRs mediate the down regulation of 
PPARγ in IEC in response to S. Typhimurium infection, as it might provide a therapeutic window of 
inducing PPARγ-dependent protective functions in the gut. 
4.2 Paper II and Paper III: SCFA induce expression of metabolic genes in the intestinal 
epithelial cells in vitro and in vivo 
In Papers II and III we focused on the role of commensal bacteria and one of their metabolites, short 
chain fatty acids (SCFA) on shaping the metabolic processes within the GI tract. We used an in vivo 
model of GF mice, which received sodium butyrate in oral gavage or were colonised with one 
commensal bacterial strain Clostridium tyrobutyricum, a butyrate producer. We also used in vitro 
models to study in more details the mechanism of action of SCFA, in particular if they can regulate the 
expression or activity or PPARγ and AhR, and in which way. 
4.2.1 Butyrate induces the expression of ANGPLT4 and CYP1A1 in colonic epithelial cells  
We first investigated the effects of stimulation of colonic cell lines with SCFAs on the expression of 
ANGPTL4, a well established PPARγ target gene (119,121) and CYP1A1, an AhR target gene (144). 
We screened various epithelial cell lines for induction of these genes after treatment with a PPARγ 
ligand - Rosiglitazone, and an AhR ligand - β-naphtoflavone (BNF). We selected HT-29 colonic 
carcinoma cell line for further experiments as in this cell line the induction of expression of 
ANGPTL4 and CYP1A1 expression was the highest. We did not observe any cross-reactivity, i.e. 
treatment with Rosiglitazone did not induce expression of CYP1A1, nor did BNF influence the 
expression of ANGPLT4. Having established the inducibility of ANGPTL4 and CYP1A1 in HT-29 
cells, we stimulated the cells with three SCFAs: acetate, propionate and butyrate to investigate if they 
could induce their expression. Butyrate was the strongest inducer of expression of ANGPTL4 and 
CYP1A1, however, with different kinetics. The expression of ANGPTL4 was induced 6 hrs after 
treatment, whereas CYP1A1 expression was induced the strongest after 24 hrs. The GI tract provides a 
complex environment where bacteria and their metabolites influence the regulation of the host's 
physiological processes in the presence of other stimuli, both nutritional and toxic. The PPARγ and 
AhR ligands are ingested with food and it is very probable the intestinal response to those dietary 
ligands is influenced by the bacteria and their metabolites. We set out to investigate what is the effect 
of a specific PPARγ or AhR ligand in combination with SCFA on the expression of ANGPTL4 and 
CYP1A1. When HT-29 cells were treated simultaneously with Rosiglitazone or BNF and butyrate a 
much higher induction of expression of ANGPTL4 and CYP1A1 was seen (Figure 10).  
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Figure 10. Expression of 
ANGPTL4 and CYP1A1 in HT-29 
treated with DMSO (0,1%), sodium 
butyrate (2mM), Rosiglitazone 
(5µM) BNF (10µM) and a 
combination of Rosiglitazone or 
BNF with butyrate. Cells were 
treated for 24 hrs prior to 
extraction of mRNA. Expression 
was analysed by qPCR and 
normalised to B-actin. Statistics: 
Students-t-test ***, p<0,001, 
against DMSO treated control 
 
 
4.2.1.1 Butyrate induces ANGPTL4 expression in PPARγ-independent manner. 
In has been suggested that butyrate activates PPARγ and in this way induces the expression of PPARγ 
target genes (62,196). Other bacterial metabolites were also reported to activate PPARγ and 
ANGPTL4 (119–121,197). We wanted to investigate if the effect of butyrate on ANGPTL4 expression 
could be attributed to the activation of PPARγ. We tried to answer this question by blocking the 
expression or activity of PPARγ by siRNA and a chemical inhibitor. Knocking down of PPARγ or 
blocking its activity did not influence butyrate-induced ANGPTL4 expression. These results suggest 
that the activation of expression of ANGPTL4 by butyrate is PPARγ-independent, which is in stark 
contrast with a recent publication by Alex and colleagues (62), in which the authors show that butyrate 
activates PPARγ in colonic epithelial cells and this activation is responsible for induction of 
ANGPTL4 expression. Many factors can be responsible for this discrepancy, including different cell 
type and culture media used. The culture media composition might be of big importance for the out-
come of butyrate treatment for two reasons. First of all the transcriptional outcome of butyrate 
treatment is dependent on metabolic status of the cells, which varies depending on glucose 
concentration in culture medium (64). It is also possible that linoleic and linolic acids present in the 
DMEM/F12 medium routinely used for cultivation of T84 cells act as PPARγ ligands. This would 
mean that the activation status of PPARγ is different in HT-29 and T84 cells, which may influence the 
outcome of butyrate treatment. Whatever the reason behind the discrepancies, it remains an interesting 
phenomenon worth investigating in more detail because it might help to understand physiological 
functions of butyrate in the gut and its role in protection against colorectal cacinoma. The observation 
that ANGPTL4 expression in HT-29 cells is independent of PPARγ led us to investigate other possible 
mechanisms of action of SCFA. ANGPTL4 promoter analysis revealed one Sp1 binding site located in 
the promoter fragment of 0,5 kbp upstream from the transcription initiation site. This promoter 
fragment was also responding to butyrate treatment, again in a PPARγ-independent manner. It was 
also responsive to treatment with Trichiostatin A (TSA), a potent histone deacetylase inhibitor, that is 
structurally unrelated to butyrate. Interestingly, TSA was shown previously to be able to activate gene 
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transcription by modulating the acetylation status of Sp1 (198). It is therefore possible that butyrate 
influences the acetylation status of not only histones but also transcription factors and possibly co-
activators and in this way exert their function as transcriptional regulators. 
4.2.1.2 Butyrate induces CYP1A1 expression in an AhR-dependent manner  
In Paper II we have established that expression of ANGPTL4 induced by butyrate in HT-29 is PPARγ-
independent. In Paper III, we investigated whether butyrate-induced expression of CYP1A1  in those 
cells is dependent on AhR. We could show that knock-down of AhR by using siRNA decreases 
butyrate induced CYP1A1 expression. Additionally, blocking of AhR activity by a chemical inhibitor 
also abrogated butyrate effect on CYP1A1 expression. CYP1A1 expression was induced by butyrate 
only after longer stimulation (longer than 8 hours) we therefore wanted to check if butyrate directly 
stimulates the AhR or if the butyrate mediated effect was dependent on synthesis of other proteins. In 
order to answer this question we blocked protein translation by treating the cells by cycloheximide 
prior to butyrate stimulation. Butyrate-induced CYP1A1 expression does not require de novo protein 
synthesis because the effects of butyrate were not blocked by cycloheximide (Figure 11).  
 
 
Figure 11. Expression of CYP1A1 in HT-29 
following 24 hrs stimulation with sodium 
butyrate after 1 hour pre-treatment with 
cycloheximide (CHX, 10µM) or vehicle 
(DMSO, 0,1%). Expression was analysed by 
qPCR and normalised to β-actin. Statistics,, 
Two Way ANNOVA, ***, p<0,001, ns, p>0,05 
 
 
 
In order to induce transcription of its target genes AhR needs to translocate from the cytoplasm to the 
nucleus, where it forms a heterodimer with ARNT which in turn allow for DNA binding at specific 
XRE. We have therefore investigated if treatment of HT-29 cells increases the nuclear pool of AhR. 
Indeed, after addition of butyrate the levels of nuclear AhR do increase (Figure 12). 
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Figure 12. Nuclear extracts from HT-29 
treated with DMSO (0,1%), sodium butyrate 
(2mM), BNF (10µM) and a combination of 
BNF and butyrate. Cells were treated for 24 
hrs prior to extraction of nuclear proteins. 
The extraction was carried using NEPER kit 
(Thermo Scientific). 30µg of protein was 
analysed using laminin as a loading control. 
Antiboides were from EnzoLife Sciences 
(AhR) and Cell Signaling (Laminin A/C).  
To our knowledge there are no reports suggesting that SCFAs might work as AhR ligands and such an 
interaction is rather improbably due to the fact that AhR ligands share planar structure, which is not 
the case for butyrate. There are however reports showing that the cell culture media (including RPMI) 
contain AhR ligands. These ligands come from light-driven degradation of tryptophan and include 
amongst others FICZ (199). The presence of AhR ligands in HT-29 cell culture medium may allow for 
basal AhR activity. We speculate that the addition of butyrate changes acetylation status of AhR or its 
co-factors, allowing for binding of a co-activators, removing co-repressors, or facilitating nuclear 
translocation. This interactions would result in increased expression of CYP1A1 that is AhR 
dependent. It is also possible that butyrate influences the chromatin structure by modifying the 
acteylation status of histones allowing for binding of AhR itself or of other proteins building the 
transcriptional machinery. The mechanism by which butyrate drives the AhR-dependent expression of 
CYP1A1 remains undiscovered and requires further detailed analysis.  
4.2.2 Oral administration of butyrate in GF mice induces the expression of ANGPTL4 and 
CYP1A1 
We have shown that butyrate induces expression of ANGPTL4 and CYP1A1 in HT-29 colonic 
carcinoma cell line. In order to confirm our results in physiological settings we gave butyrate solution 
intragastrically to GF mice. Gavage with butyrate stimulated the expression of ANGPTL4 and 
CYP1A1 in the epithelial cells of the distal small intestine, confirming the stimulatory effect of 
butyrate on the expression of ANGPTL4 and CYP1A1 in the GI tract. Administration of butyrate is 
effective in GF mice, which do not have any bacterially-produced SCFAs. However, the high 
concentrations of SCFAs in the colon of  a mouse harbouring normal microbiome would most 
probably mask any effect of butyrate administered by gavaging. Additionally, butyrate gavage did not 
induce any changes in gene expression in the colon, most probably due to reduced transfer through the 
ceacum or earlier absorption by epithelial cells. Although significant amounts of SCFAs are found in 
the small intestine, it is the colon where the concentration of butyrate is the highest. We have therefore 
chosen to use a butyrate producing bacterial strain to achieve a more physiological setting and to see if 
SCFA producers were able to mimick the effect of exogenously supplemented SCFA. 
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4.2.3 Clostridium tyrobutyricum induces the expression of ANGPTL4 and CYP1A1 in intestinal 
epithelium 
Having established that butyrate induces the expression of ANGPTL4 and CYP1A1 expression in 
intestinal epithelial cells in vitro and in vivo,  we asked ourselves if similar effect could be achieved by 
directly using a butyrate producing bacteria. We have chosen a butyrate producer Clostridium 
tyrobutyricum, a strain  previously shown to prevent colitis in mice (200,201). C. tyrobutyricum is a 
part of normal commensal flora in mice and it is also present in cheese, therefore is a feasible bacteria 
to use in intervention studies in the future. Another reason for choosing this particular species was the 
fact that it is known to produce mostly butyrate and not the other SCFA: propionate and acetate, which 
was important since we have used butyrate in our in vitro studies as the most potent of the three 
SCFAs tested. We have tested the effects of C. tyrobutyricum on the expression of ANGPTL4 and 
CYP1A1 both in vitro and in vivo. We first monocolonised GF mice with C. tyrobutyricum in order to 
establish if the effects mediated by oral administration of butyrate are mimicked by the presence of a 
butyrate producing bacteria. Expression of ANGPTL4 and CYP1A1 was higher in the colon and distal 
small intestinal epithelial cells of monocolonised mice than in GF mice. We have also compared the 
levels of CYP1A1 and ANGPTL4 in C. tyrobutyricum monocolonised mice and specific pathogen free 
mice, harbouring normal microbiota. We found that the levels of CYP1A1 and ANGPTL4 expression 
was comparable between colonic epithelial cells of C. tyrobutyricum and SPF. However, in the small 
intestine the SPF mice had lower expression levels of ANGPTL4 and CYP1A1 than C. tyrobutyricum 
monocolonised mice or even the GF mice in case of ANGPTL4. Lower levels of ANGPTL4 
expression in the small intestine of SPF mice as compared to germ free mice was previously reported 
(86,202). The reason behind the differential regulation of ANGPTL4 and CYP1A1 expression by the 
entire microbiome in SPF mice and C. tyrobutyricum is not know. One explanation might be, that the 
flora inhabiting the small intestine is more diverse and have other functions, apart from producing 
SCFA, which results in overall lower expression of CYP1A1 and ANGPTL4. 
In order to be able to distinguish the effects caused by direct contact between bacteria and the 
eukaryotic cells and the effects mediated indirectly by bacterial metabolites we used in vitro system 
based on HT-29 cells. We stimulated HT-29 cells with live and heat-inactivated C. tyrobutyricum as 
well as with different bacterial culture media. From these experiments we concluded that it is indeed 
the soluble bacterial metabolites and not membrane-bound components of bacteria that play a major 
role in induction of ANGPTL4 and CYP1A1 expression. One cannot, however, formally exclude the 
presence of metabolites other than SCFAs in this soluble fraction. 
4.3 Paper III:  Cross-talk between AhR, gut microbiota and energy homeostasis 
Given that SCFA and intestinal microbiota influence CYP1A1 expression in an AhR dependent 
manner we sought to investigate in more detail the cross-talk between the AhR and the microbiome. 
AhR is an important regulator of intestinal homeostasis and by regulating the activity of ILC22 and 
development of T-cells, AhR influences the production of antimicrobial peptides. AhR activity could 
therefore regulate the composition and function of the intestinal of microbiota. We used the AhR KO 
mice, in which AhR gene was deleted to test this hypothesis.  
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4.3.1 Deletion of the AhR changes the composition of small intestinal microbiota 
Profound changes in the composition of intestinal microbiota have been reported for  mice lacking 
TLR5 and NLRP6 (203,204). In both cases the disbalance in microbial ecology results in the 
development of colitis that could be transmitted to WT mice that received the microbiota from the KO 
mice. We first sought to investigate if deletion of AhR compromises the microbial status quo in the 
intestine. We collected the content of the distal part of the small intestine, the colon as well as faecal 
material. To eliminate external influences, we compared only co-housed littermates of AhR 
heterozygous crosses. Thus both AhR KO and AhR WT mice had equal chances to acquire the same 
bacterial flora. There were no differences between AhR KO and WT mice when faecal or colonic 
microbiota were compared. However, the comparison of prevalence of bacterial phyla and classes 
inhabiting the small intestine revealed significant differences between mice expressing the AhR and 
AhR-deficient mice. The prevalence of Actinobacteria, Tenericutes and Bacteroidetes was lower and 
the prevalence of Firmicutes was higher in the intestine of AhR KO mice.  We also observed 
significant difference in prevalence of two classes of bacteria belonging to the Firmicutes phyla. The 
Bacilli class was more abundant and the Clostridia class less so in the intestine of the AhR KO mice. 
Bacteria that  belong to the phylum Bacteroidetes as well as the ones that belong to the class Clostridia 
within the Firmicutes phyla are the main contributors to the production of SCFA in the GI tract. We 
hypothesise that the AhR KO mice have decreased fermentation ability, and thus lower levels of 
SCFA in the GI tract. Although lower levels of SCFA in the intestine of AhR KO is speculative it does 
however remain an interesting possibility because SCFA have anti-inflammatory effects and AhR KO 
mice are more prone to chemically and bacterially induced colitis (34,150,205–209). The fact that 
there was no difference in the composition of faecal and colonic microbiota between the AhR WT and 
AhR KO mice, but we did observe major shifts in the proportions of small intestinal bacteria is of 
great importance. The majority of studies aiming to characterize the differences between various 
genetic or environmental conditions is usually based on comparisons of faecal material because it is 
easily available. However, the knowledge gained by sequencing bacterial DNA from faeces might not 
be as informative as previously though. There might be changes in the populations of bacteria 
inhabiting the small intestines which are not detectable when comparing the faecal microbiome. Our 
results are in accordance  with a report aiming to characterize the "active" microbiome at various sites 
along the GI tract, that found that there are important differences between the fecal and intestinal 
bacterial composition (54). The shift in the composition of intestinal microbiota favoring the 
prevalence of anaerobic fermenting bacteria (including Clostridia) occurs mainly during the weaning 
period. Interestingly, the AhR KO mice have altered weight gain during that phase of development. It 
is therefore an interesting question is  if the changes in the composition of microbiota observed in the 
AhR KO have a causative effect on the growth retardation of these mice or if they may account for 
higher susceptibility of these mice to intestinal inflammation. It would be of great interest to perform 
microbiome transfer experiments to confirm the role of bacterial imbalance in the intestine of the AhR 
KO in susceptibility of these mice to colitis. Apart from higher susceptibility for intestinal 
inflammation the changes in bacterial composition are also reported to cause obesity and metabolic 
disorders in mice (88,210). In the final part of Paper III we investigated if AhR can play an important 
role in regulating energy balance. 
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4.3.2 AhR is an important regulator of energy homeostasis 
Several reports indicated a role of AhR in the regulation of energy balance and metabolism. Many of 
these studies were performed in conjunction with the investigation of toxicity of man-made 
environmental pollutants in animal models. Chronic administration of TCDD in mice, for instance 
results in profound changes in expression of genes regulating cholesterol synthesis, de novo 
lipogenesis and glycolisis. (159). Acute exposure to TCDD lowers the expression of genes involved in 
gluconeogenesis in the liver (160)  and decreases glucose transport to the adipose tissue (161). 
Administration of 3MC in C57Bl/6J mice resulted in fat accumulation in the liver and development of 
liver steatosis in conjunction with increased levels of PPARα mRNA in the liver, probably due to 
increased expression of fatty acid translocase (FAT a.k.a. CD36) (162). On the other hand AhR KO 
mice have lower expression of PPARα and genes coding for enzymes involved in β-oxidation of fatty 
acids (Paper III and (164)). Altogether these animal models indicate a strong link between the 
expression and activity of the AhR and metabolism of fat and glucose, mainly β-oxidation of fatty 
acids and gluconeogenesis. Gluconeogenesis and β-oxidation of fatty acids are two metabolic 
processes that are active mostly during caloric restriction or fasting, when the easily available reserve 
of glucose and glycogen are exhausted and there is a need to retrieve energy from fat deposits. There 
were however no reports to our knowledge that investigated the role of the AhR in the regulation of 
metabolic processes occurring during fasting in mice. In order to study in detail the role of AhR in the 
regulation of fasting-associated metabolic processes we embarked on global scanning of metabolites 
present in the blood, liver and muscle tissue of AhR KO and AhR WT mice after 12 hours of food 
removal. This unsupervised approach allowed us to dig deep into the possible molecular mechanisms 
and discover several pathways affected in the KO mice during fasting. Here we report for the first time 
that AhR is an important factor regulating oxidation of fats in the liver and production of ketone 
bodies. Metabolic NMR profiling also revealed higher levels of lactate, pyruvate and alanine in the 
plasma of AhR -/- mice suggesting increased rate of glycolysis in peripheral tissues.  
Presence and concentration of many of environmental pollutants that are ligands for the AhR, in 
human serum is positively correlated with diabetes and metabolic syndrome (165). One of the 
hallmarks of metabolic syndrome is elevated fasting glucose levels as a consequence of glucose 
intolerance in peripheral tissues, up-regulated gluconeogenesis even in the presence of glucose in the 
blood and disrupted mitochondrial oxidation of fatty acids. Mitochondrial dysfunction has been 
recently associated with increased levels of AhR-ligands in human blood serum in an independent 
study (166). We therefore fed the AhR KO mice semi-synthetic chow in which the  proportion of 
calories coming from fat is about 40%. This chow is called western diet (WD) as it is supposed to 
mimic the dietary habits of westernised, developed countries (including Europe and United States of 
America). Such diet is associated with development of obesity and metabolic diseases in humans and 
in mice (211,212). Feeding adult AhR KO and WT mice western diet for 11 weeks resulted in 
increased body weight gain as compared to normal chow (R36) fed mice. We did not however observe 
any differences between the AhR KO and AhR WT mice. To assess glucose intolerance, we performed 
an oral glucose tolerance test. We observed that AhR KO mice had lower fasting glucose levels and 
improved glucose tolerance than AhR WT mice. The absence of AhR signalling might be beneficial 
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during dietary challenge, down-regulating gluconeogenesis in the liver and switching the metabolism 
from fats to glucose which result in the lower fasting glucose levels of AhR KO mice. 
Most of the studies trying to answer the role of AhR in regulation of physiological processes is done 
using male mice. However many of the environmental pollutants linked with obesity and metabolic 
problems have oestrogen-like properties and exposure to such chemicals leads to disturbed hormonal 
balance. Additionally AhR may directly and indirectly interact with oestrogen receptor itself (153), 
giving yet another twist to the role of oestrogen-like chemicals in development of metabolic 
syndrome. We therefore used females AhR KO and AhR WT mice to study the development of diet-
induced obesity and glucose intolerance. We found that AhR female mice were protected against 
western-diet induced weight gain and glucose intolerance (Figure 13).  
A.     B. 
 
 C.                 D.              E. 
 
Figure 13. Metabolic parameters of female AhR KO and AhR WT mice fed Western Diet.  
A. Weight changes. B. weight after 11 weeks of feeding. Statistics T-test *, p<0,05; **, p<0,01; ***, 
p<0,001. Bars and error bars show means +/- SEM.  C-E. Oral glucose tolerance test. Changes of 
glucose concentration in blood after oral administration of glucose (2g/kg) (C), Area under curve (D) 
and fasting glucose levels (E). Statistics One-Way ANNOVA: *, p<0,05; **, p<0,01;  Bars and error 
bars show means +/- SEM.  
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Previous studies have shown that WT C57/Bl6 female mice do appear to be significantly less 
susceptible to the metabolic lesions brought about by fat-rich diets (213). In that study both males and 
females gain weight, but the female are able to handle the consequences of higher visceral fat better 
than the males. 
Given that the AhR KO males undergo changes in the microbiota and exhibit metabolic variables 
leading to inefficient energy utilisation, one could speculate that similar conditions in the female AhR 
KO mice under WD allows the shunting of excess energy from storage to usage, hence having no 
appreciable weight gain. This is at present speculative, and would be of interest to explore in terms of 
underlying molecular mechanisms and implications for gender-based therapies.  
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5. CONCLUDING REMARKS AND PERSPECTIVES 
When I first registered as a PhD student in October 2008, the field of human commensal microbiology 
had just became a very hot topic. Virtually every day new data and new knowledge was made 
available to the world. At this time I could describe the components of my project plan as "The Good, 
the Bad and the Ugly" making a reference to Clint Eastwood's famous Western movie. The Good was 
the PPARγ, protecting us from pathogens and preventing too strong immunological responses. The 
Bad was the AhR, at this time mostly known for mediating toxic effects of dioxins and other 
environmental pollutants having immunosupressive and carcinogenic effects. And the Ugly, were the 
intestinal microbiota, due to their obscure function and unknown properties. The composition of the 
intestinal microbiota was first characterised in the late 1970s, it was however not before the 16S rRNA 
typing techniques conquered the field that we got the full insights into which bacteria inhabit our 
intestines. The two big collaborative projects: The NIH Human Microbiome Project 
(http://commonfund.nih.gov/hmp/index) and the European Meta-HIT Consortium 
(http://www.metahit.eu) were the main contributors to the knowledge in this field. These two large 
groups of scientists sequenced and characterised the vast majority of bacterial DNA that could be 
extracted from human faeces. The majority of results of their work and the work of many other groups 
on intestinal bacterial composition were published between year 2005 and 2011 (reviewed in (61)). It 
is therefore only recently that we have gained the knowledge about who is there. At the moment huge 
efforts are undertaken to understand what they are doing there. We are just at the beginning of a 
journey to understand the role, mechanisms and importance of our microbiome in regulating the host's 
physiological processes and shaping the balance between health and disease. Much has also be learnt 
about how our bodies adjust to changes in the microbiome and how our physiology shapes the 
composition and functionality of the microbiome. This work is a modest attempt to unravel some of 
the mysteries and conundrums behind this bidirectional interaction. 
In Paper I we focused on the interaction of a pathogenic bacteria with the host and the consequences it 
has for the progression of intestinal inflammation. We could show that infection with S. Typhimurium 
decreases the levels of PPARγ in the IEC and that deletion of PPARγ results in increased 
inflammatory response and tissue damage. This might be mediated by several possible mechanisms. 
One of them is the lack of NFκB transrepression in the absence of PPARγ. It was previously shown 
that PPARγ is able to influence nuclear shuttling of NFκB, resulting in lowered expression of pro-
inflammatory genes. In that study the anti-inflammatory effects of PPARγ were induced by a 
commensal bacteria Bacteroidetes thetaiotaomicron (214), via a yet unknown mechanism. 
B.thetaiotaomicron belongs to the Bacteroidetes phylum and is an anaerobic bacteria that produces 
SCFAs acetate and propionate as products of fermentation (87). Other fermenting bacteria that were 
shown to ameliorate intestinal inflammation are Clostridium butyricum and Clostridium 
tyrobutyricum, belonging to the Firmicutes phylum (200,201). It is therefore possible that the changes 
in bacterial composition induced by streptomycin treatment contribute to the development of colitis 
upon S. Typhimurium infection. Indeed streptomycin was shown to decrease the amount of SCFA and 
some SCFA producers (Firmicutes) in the mouse intestine (215). Clostridia, including C. butyricum 
and C. tyrobutyrium,  exert their effect via TLR2 in vitro and in vivo (201,216). Additionally, 
gavaging of mice with butyrate induces the expression of TLR2 in the IEC (Figure 14). In paper I we 
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showed that the downregulation of PPARγ in response to S. Typhimurium infection is TLR4 
independent, however other TLRs, like TLR2 play an important role in mediating this effect. It is 
probable due to the fact that one of the S. Typhimurium MAMPs  - curli fibrils is recognized by TLR2. 
This recognition is needed for tightening the epithelial barrier which in turn prevents invasion of S. 
Typhimurium to the lamina propria (193). We speculate that decreases in SCFA and SCFA producers 
in the intestine caused by streptomycin treatment lowers the TLR2 dependent signaling, which loosens 
the epithelial barrier predisposing mice to colitis. It remains an open question if deletion of PPARγ in 
the IEC influences the composition of microbiome, for example by lowering the amounts of 
fermenting microbiota (similarly to the effect observed in the AhR KO mice in Paper III), which 
would be yet another way to predispose these mice to colitis. This effect could be achieved for 
example by decreased expression of TFF3 regulating the mucosal integrity, by changing the immune 
landscape in the gut or by yet unidentified mechanisms. 
 
 
Figure 14. Expression of TLR2 in IEC of GF mice gavaed 
with water or sodium butyrate (1g/kg) 24 and 6 hours prior to 
sacrifice. Gene expression was analysed by qPCR and 
normalised to B-actin. Statistics: Students-t-test *, p<0,05,  
 
 
Another interesting observation connecting the intestinal microbial composition with colitis is that a 
mixture of Clostridia species was able to ameliorate intestinal colitis as well by activating the 
expression of IL-10 in Treg cells (201). AhR was shown to regulate IL-10 production in Treg cells and 
in Paper III we show that C. tyrobutyricum was able to transcriptionally activate AhR. It is therefore 
possible that streptomycin induced changes in the intestinal microbiome lead to downregulation of 
AhR-mediated signaling, providing yet another explanation as how the colonisation resistance works. 
We and others could show the dependence of PPARα expression on the presence of AhR (Paper III 
and (164)), but the AhR and PPARγ have not been robustly linked at this point in time, to our 
knowledge. However, these receptors share the co-activators and might be indirectly linked via 
bacterial interactions.  
PPARγ, AhR, ANGPTL4 and LCN2 are all multi-functional proteins occupying the inflammation-
metabolism junction. PPARγ protects against intestinal colitis, while at the same time regulates the 
expression of metabolic enzymes and storage of fat. This laboratory has also shown that PPARγ is 
amenable to post-translational regulation by bacteria (119,121,214). AhR is an important regulator of 
response to fasting, and appears to govern PPARα which is fundamental for energy extraction from 
lipids. AhR at the same time influences the composition of the microbiome in the gut and mediates 
immune responses to intestinal pathogens and environmental pollutants. ANGPTL4, although mostly 
studied as an adipokine involved in usage of fatty acids was also shown to prevent formation of foam 
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cells and in this way to protect against fatty-acid induced inflammation (217). LCN2 is an 
antimicrobial peptide keeping intestinal bacteria at safe distance from the IECs in the intestine. During 
infection it can also mediate remodeling of the intestinal wall by forming complexes with MMP9. 
Interestingly, LCN2 was postulated to be an acute phase response protein secreted from the liver in 
response to infection and a biomarker for renal injury and ongoing inflammation (218). Some studies 
have even linked LCN2 to the development of metabolic syndrome in humans, further pointing to the 
link between systemic inflammation and metabolic diseases (219). We now know from our own work 
and from the work of others that PPARγ, AhR as well as ANGPTL4 and LCN2 can be directly or 
indirectly regulated by the intestinal microbiome. Additionally nutritional ligands have been identified 
for PPARγ and AhR. Crucially, it has also been shown that composition of bacteria in the GI tract is 
dependent on diet (12,57,220,221). The rapidity of diet induced changes of the microbiota requires 
efficient sensory receptors and genetic effectors. Ligand-activated transcription factors are a unique 
group that can work simultaneously as receptors and effectors and respond to nutritional cues. 
Paper II and Paper III deal directly with microbiome derived cues that can impact on host metabolic 
properties. SCFA was chosen as a model microbial molecule as it represents the symbiotic nature of 
the microbiota and the diet. SCFA production is firmly dependent on bacterial fermentation of dietary 
fibres. Beyond its importance in intestinal immunity and colonocytes survival, SCFAs act as a 
metabolic mediator, in this case we believe through ANGPTL4 (Paper II). We and others have shown 
that gut microbiota driven ANGPTL4 has ameliorating effects on fat storage (86,121). More recent 
studies indicate that ANGPTL4 is crucial for reducing intestinal lipase activity (222). This prevents 
intestinal lipid overload, in an ANGPTL4-mediated manner, as previously shown in cardiomyocytes 
and macrophages (217). Hence, it tempting to speculate that that the diet-microbiota interplay that 
produces a steady stream of SCFAs has a crucial role in downstream lipid processing in the host. 
More subtle effects of the diet-microbiota marriage on metabolism are seen in Paper III, where a 
bidirectional relationship between AhR and microbiome is proposed. The absence of a functional AhR 
changes the composition of the microbiota but crucially only in the small intestine. Whether the 
microbiota population is sculptured by epithelial or immune factors under the direction of AhR 
remains to be elucidated. What is of interest is exactly how far the microbiome changes can double 
back and impact of the metabolic properties seen in the AhR KO mice, e.g. compromised lipid 
metabolism in the liver. These insights are useful when considering different approaches to understand 
and treat chronic immune and metabolic disorders.  
The microbiome, e.g. SCFAs influences expression of AhR target genes in the intestine. This 
microbiome induced expression of AhR may indicate a mechanism to increase sensitivity towards 
AhR ligands. In the course of mammalian development, governance of AhR activity by SCFA can 
occur primarily after weaning, when there is sufficient dietary complex carbohydrate content. Milk 
oligosaccharides, together with maternal microbiota may have similar effects before weaning. The 
importance of SCFA-driven CYP1A1 expression in the intestine is indeed significant, as intestinal 
CYP1A1 reduces the burden of processing xenobiotics in the liver (223). In the early stages of 
development, the clearance of food-derived xenobiotics without impinging much on liver activity is 
crucial to ensure proper liver function for the purpose of energy harvest. Tellingly TLR2, a PRR which 
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we show to be inducible by SCFA in the intestine, is essential for of intestinal CYP1A1 activity (223). 
TLR2, like AhR and PPARγ also occupies the interface of immunity and metabolism and is open to 
regulation by the microbiome. 
The dialogues between immunity and metabolism is a prerequisite for growth, reproduction and 
survival, the common currency of which is energy availability. It is essential to maintain a cordial 
intercourse, as any disruption will result in a cascade of inflammatory and metabolic diseases. This 
will inadvertently divert energy usage from maintenance and growth to protection and defense.  
Complex organisms as ourselves have reduced the burden of maintaining this crosstalk, by "out 
sourcing" certain functions in maintaining this peaceful relations to the microbiota. The microbiota in 
turn has recruited an array of host responders to rapidly and effectively manage the energy needs 
(survival) of both the host and the microbial community.   
Multiple roles and functions of PPARγ, AhR, ANGPTL4, TLR2 and LCN2 have made them great 
candidates to study the inflammation-metabolism interface within the gut epithelium. Much, however, 
remains unknown and we are only now beginning to appreciate how these and other proteins are 
interconnected and influence each other's function in response to nutritional or bacterial cues which 
then together shape the balance between health and disease. The interaction between the microbiome, 
PPARγ and AhR require much more attention and investigation before we will be able to translate the 
knowledge into methods for disease prevention or treatment.  
To conclude my work presented in this PhD thesis, I would like to quote the Nobel Prize Laureate in 
literature, José Saramago. Although he most probably used it in a metaphorical and psychological 
sense, I think it perfectly describes the biology of human kind and our dependence on so many other 
organisms, whose roles are barely understood. 
 
Saberemos cada vez menos o que é um ser humano.  
Each time, we know less of what a human being is. 
- José Saramago 
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